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II  Guideline Application
=========================

Purpose and objectives
----------------------

The most important reason to update this interdisciplinary guideline was the epidemiological impact of breast cancer and its associated burden of disease, both of which are still high. This is the context in which the impact of new management concepts and their implementation needed to be evaluated.

Targeted areas of patient care
------------------------------

The guideline covers outpatient, inpatient and rehabilitative care.

Target patient groups
---------------------

The recommendations of the guideline are aimed at all women and men who develop breast cancer as well as their relatives.

Target user groups/Target audience
----------------------------------

The recommendations of the guideline are addressed to all physicians and professionals who provide screening services for women or care for patients with breast cancer (gynecologists, general practitioners, human geneticists, radiologists, pathologists, radio-oncologists, hemato-oncologists, psycho-oncologists, physiotherapists, nursing staff, etc.).

Adoption of the guideline and period of validity
------------------------------------------------

This guideline is valid from December 1, 2017 through to November 30, 2022. Because of the contents of this guideline, this period of validity is only an estimate. It may become necessary to update the guideline because of new scientific evidence and knowledge as well as new developments affecting the methodology used for these guidelines. It is also necessary to edit and revise the guidelineʼs contents and re-evaluate and revise the key statements and recommendations of the guidelines at regular intervals.

III  Methodology
================

Basic principles
----------------

The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and regulations for the different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest class (S3). The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was subdivided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest class (S3) combines both approaches. This guideline is classified as: S3.

Grading of evidence
-------------------

This guideline used the 2009 version of the system of the Oxford Centre for Evidence-based Medicine (levels 1 -- 5) to classify the risk of bias in identified studies. This system classifies studies according to various clinical questions (benefit of therapy, prognostic value, diagnostic validity). For more detailed information, abbreviations and notes, see: <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>

Grading of recommendations
--------------------------

While the classification of the quality of the evidence (strength of evidence) serves as an indication of the robustness of the published data and therefore expresses the extent of certainty/uncertainty regarding the data, the classification of the level of recommendation reflects the results of weighing up the desirable and adverse consequences of alternative approaches. This guideline shows the level of evidence for the underlying studies as well as the strength of the recommendation (level of recommendation) for all evidence-based Statements and Recommendations. This guideline differentiates between three levels of recommendation ( [Table 4](#TB6464630-4){ref-type="table"} ). The levels reflect the strength of the respective recommendation and are also mirrored in the terms used to formulate the recommendation.

###### 

**Table 4**  Grading of recommendations.

  Level of recommendation   Description                             Syntax
  ------------------------- --------------------------------------- -------------------
  A                         strong recommendation, highly binding   must/must not
  B                         recommendation, moderately binding      should/should not
  0                         open recommendation, not binding        may/may not

Statements
----------

Statements are expositions or explanations of specific facts, circumstances or problems with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on trial results or expert opinions.

Expert consensus
----------------

As the expression implies, this term refers to consensus decisions taken specifically with regard to Recommendations/Statements without a previous systematic search of the literature (S2k) or when evidence is lacking (S2e/S3). The term "Expert Consensus" (EC) used here is synonymous with terms such as "Good Clinical Practice" (GCP) or "Clinical Consensus Point" used in other guidelines. The level of recommendation is graded as previously described in the Chapter "Grading of recommendations", but the grading is only presented semantically ("must"/"must not" or "should"/"should not" or "may"/"may not") without the use of symbols.

Guideline report
----------------

To edit and update the various topic areas, an adaptation of existing guidelines was planned for around 80% of Statements and Recommendations in accordance with the AWMF Guidance Manual. To do this, a systematic search was carried out for source guidelines developed specifically for women with breast cancer and published after 2013. Findings were compared with the IQWiG guideline report No. 224 (Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Recommendations für das DMP Brustkrebs \[Systematic guideline search and appraisal as well as extraction of relevant recommendations for a breast cancer DMP\]). A further inclusion criterion was compliance with methodological standards. Guidelines were included if they complied with at least 50% of Domain 3 (Rigour of Development) of the AGREE II instrument. A corresponding search and evidence assessment was specified in accordance with AWMF guidelines (systematic search, selection, compilation of evidence tables) for those recommendations which could not be adapted or had to be newly created. For newly developed Recommendations and Statements, appropriate key questions were formulated and a systematic search was carried out using aggregated sources of evidence (meta-analyses, systematic reviews, etc.) as well as individual publications in specific cases. A suitable list of titles and abstracts up to and including the identification of the full text were selected by two independent raters. After the search and selection processes were completed, the necessary evidence tables which formed the basis for the consensus conferences were compiled by the Methods group (financial support was provided and allowed a researcher to be specifically hired for this purpose). The classification system of the Oxford Centre for Evidence-based Medicine (version 2009) was used to grade the evidence. To update this guideline, Recommendations and Statements were adopted and levels of recommendation ( [Table 4](#TB6464630-4){ref-type="table"} ) were determined during two structured consensus conferences which were preceded by a preliminary online ballot.

The guideline report provides an overview of the search strategies and selection processes used to select the literature and to formulate and grade the recommendations.

IV  Guideline
=============

1  Treatment of primary breast cancer
-------------------------------------

### 1.1  Surgical treatment for invasive carcinoma

#### 1.1.1  General recommendations

  No.                                                                                                                                                                                                           Recommendations/ Statements                                                                                 EG   LoE             Sources
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---- --------------- --------------------------------
  4.19.                                                                                                                                                                                                         a\) The basic therapy for all non-advanced breast cancers is complete resection of the tumor (R0 status).   A    1a              [@R6464630-1] ,  [@R6464630-2]
  b\) The resection margin status has a prognostic effect on invasive breast cancer. There is a significant association between resection margin status (positive vs. negative) and local rate of recurrence.   A                                                                                                           1a   [@R6464630-3]   

#### 1.1.2  Breast-conserving therapy

Randomized clinical studies have shown that if certain clinical and histological parameters are taken into account, breast-conserving therapy achieves identical survival rates to those of mastectomy.

  No.                                                                                                                                                                                                                                                       Recommendations/ Statements                                                                                                                                                                             EG   LoE   Sources
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- ----------------------------------------------------------------------------------------------------------------------
  4.20.                                                                                                                                                                                                                                                     a\) The goal of surgical therapy is complete removal of the tumor. Breast-conserving therapy (BCT) followed by full breast radiotherapy is equivalent to mastectomy alone in terms of survival rates.        1a    [@R6464630-4] ,  [@R6464630-5] ,  [@R6464630-6] ,  [@R6464630-7] ,  [@R6464630-8] ,  [@R6464630-9] ,  [@R6464630-10]
  b\) All appropriate patients, whether or not they have previously had primary systemic therapy, must be informed about the possibility of breast-conserving therapy (BCT) and about mastectomy with the options of primary or secondary reconstruction.   EC                                                                                                                                                                                                                 

#### 1.1.3  Mastectomy

  No.                                                                                                                                                                                                  Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                       EG   LoE                                                                                                                                            Sources
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  4.21.                                                                                                                                                                                                a\) Mastectomy must be performed if any of the following indications are present:Incomplete removal of the tumor (incl. any intraductal component), even after secondary resectionInflammatory breast cancer (generally even in cases with pathological complete remission)When follow-up radiation of the breast after breast-conserving therapy is contra-indicated but radiation is absolutely indicatedat the request of the patient who has been fully informed about her range of options   A    2b                                                                                                                                             [@R6464630-11] ,  [@R6464630-12] ,  [@R6464630-13]
  b\) If the resection margins are tumor-free, mastectomy may also be performed as a skin-sparing procedure with or without preservation of the NAC.                                                   0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2a   [@R6464630-14] ,  [@R6464630-15] ,  [@R6464630-16] ,  [@R6464630-17]                                                                           
  c\) Depending on the tumor location and tumor size, mastectomy may be necessary in individual cases, even if multiple cancers are present.                                                           0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2a   [@R6464630-18] ,  [@R6464630-19] ,  [@R6464630-20] ,  [@R6464630-21] ,  [@R6464630-22] ,  [@R6464630-23] ,  [@R6464630-24] ,  [@R6464630-25]   
  d\) Contralateral prophylactic mastectomy to reduce the risk of contralateral breast cancer should not be carried out in non-mutation carriers or patients with no evidence of high familial risk.   B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2b   [@R6464630-26] ,  [@R6464630-27] ,  [@R6464630-28]                                                                                             

#### 1.1.4  Reconstructive plastic surgery procedures

  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                 EG   LoE   Sources
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- ----------------------------------------------------
  4.22.   Every patient scheduled for mastectomy must be informed about the options of having immediate or subsequent breast reconstruction or the option of forgoing reconstructive procedures; these patients should be offered the opportunity to contact other similarly affected people and self-help groups or organizations.   A    2b    [@R6464630-16] ,  [@R6464630-29] ,  [@R6464630-30]

#### 1.1.5  Axillary surgery

  No.                                                                                                                                                                                                                                                                         Recommendations/ Statements                                                                    EG   LoE
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---- ----------------------------------------------------
  4.23.                                                                                                                                                                                                                                                                       a\) Axillary staging is an essential part of the surgical therapy of invasive breast cancer.   EC   
  b\) Staging must include sentinel lymph node biopsy (SLNB) even if the lymph node status is unremarkable on palpation and ultrasound.                                                                                                                                       A                                                                                              1a   [@R6464630-30] ,  [@R6464630-31] ,  [@R6464630-32]
  c\) Clinically significant lymph nodes that are negative on biopsy should also be resected during SLNB.                                                                                                                                                                     B                                                                                              2b   [@R6464630-30] ,  [@R6464630-33]
  d\) Patients with pT1--pT2/cN0 tumors who undergo breast-conserving surgery followed by percutaneous radiation by tangential opposing fields (tangential radiation therapy) and who have one or two positive sentinel lymph nodes should not undergo axillary dissection.   B                                                                                              1b   [@R6464630-31]
  e\) Patients who have mastectomy or to whom the above-listed criteria do not apply should undergo axillary dissection or receive axillary radiotherapy.                                                                                                                     B                                                                                              1b   [@R6464630-31] ,  [@R6464630-34]
  f\) Targeted therapy of the lymph drainage areas (surgery, radiotherapy) must not be carried out if the patient only has micro-metastasis.                                                                                                                                  B                                                                                              1b   [@R6464630-35] ,  [@R6464630-36]
  g\) Patients treated with primary systemic therapy (PST) and whose lymph node status on palpation and ultrasound is negative prior to treatment should have SLN after PST.                                                                                                  B                                                                                              2b   [@R6464630-37] ,  [@R6464630-38]
  h\) Patients treated with primary systemic therapy (PST) whose nodal status on punch biopsy is positive (cN1) prior to treatment but whose nodal status after PST is clinically negative (ycN0) should undergo axillary dissection.                                         B                                                                                              2b   [@R6464630-38] ,  [@R6464630-39]
  i\) Patients treated with primary systemic therapy (PST) who have a positive nodal status before and after PST must undergo axillary dissection.                                                                                                                            EC                                                                                                  
  j\) Patients must not undergo axillary staging if there is evidence of distant metastasis.                                                                                                                                                                                  EC                                                                                                  

### 1.2  Adjuvant radiation therapy for breast cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                       EG    LoE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  4.36.   After breast-conserving surgery for invasive carcinoma the affected breast must be treated with radiotherapy.\                                                                                                                                                                                                                                                                                    A     1a    [@R6464630-40] ,  [@R6464630-41] ,  [@R6464630-42] ,  [@R6464630-43] ,  [@R6464630-44] ,  [@R6464630-45] ,  [@R6464630-46] ,  [@R6464630-47]
          Provided the resection margins were tumor-free, patients with a clearly limited life expectancy (\< 10 years) and a small (pT1), node-negative (pN0), hormone receptor-positive HER2-negative tumor and endocrine adjuvant therapy may avoid radiation therapy and accept the increased risk of local recurrence after receiving individual counselling.\                                                     
          Note for all Recommendations: all single positions are OR conjunctions. AND conjunctions are represented by "and".                                                                                                                                                                                                                                                                                            

  4.37.   Radiotherapy of the breast should be administered in hypofractionated doses (total dose: approx. 40 Gy in approx. 15 -- 16 fractions over approx. 3 to 5 weeks) or may be administered as a standard fractionated regimen (total dose: approx. 50 Gy in approx. 25 -- 28 fractions over approx. 5 -- 6 weeks).                                                                                    B/0   1a    [@R6464630-48] ,  [@R6464630-49] ,  [@R6464630-50] ,  [@R6464630-51] ,  [@R6464630-52] ,  [@R6464630-53] ,  [@R6464630-54]

  4.38.   Local dose escalation (boost radiotherapy) of the tumor bed reduces the local rate of recurrence in the breast without achieving a significant survival benefit.\                                                                                                                                                                                                                                 A/B   1a    [@R6464630-55] ,  [@R6464630-56] ,  [@R6464630-57] ,  [@R6464630-58]
          Boost radiotherapymust therefore be carried out in all patients aged ≤ 50 years andshould only be carried out in patients aged \> 51 years if they have an increased risk of local recurrence (G3, HER2-positive, triple-negative, \>T1).                                                                                                                                                                     

  4.39.   Partial breast irradiation alone (as an alternative to secondary whole breast irradiation) may be carried out in patients with a low risk of recurrence.                                                                                                                                                                                                                                          0     1a    [@R6464630-59] ,  [@R6464630-60] ,  [@R6464630-61] ,  [@R6464630-62] ,  [@R6464630-63] ,  [@R6464630-64]

  4.40.   Postoperative radiotherapy of the thoracic wall after mastectomy reduces the risk of loco-regional recurrence and improves the survival of patients with locally advanced, node-positive breast cancer.                                                                                                                                                                                           A     1a    [@R6464630-65]

  4.41.   Radiation of the thoracic wall after mastectomy is indicated in the following situations:\                                                                                                                                                                                                                                                                                                        A     1a    [@R6464630-65] ,  [@R6464630-66] ,  [@R6464630-67] ,  [@R6464630-68] ,  [@R6464630-69] ,  [@R6464630-70] ,  [@R6464630-71] ,  [@R6464630-72] ,  [@R6464630-73] ,  [@R6464630-74] ,  [@R6464630-75] ,  [@R6464630-76] ,  [@R6464630-77] ,  [@R6464630-78] ,  [@R6464630-79]
          pT4pT3 pN0 R0 when additional risk factors are present (lymph node invasion (L1), G3 grading, premenopausal, age \< 50 years)R1/R2 resection and no possibility of a second curative resectiona) Post-mastectomy radiation must be carried out as a standard procedure if more than 3 axillary lymph nodes are affected.\                                                                                     
          b) If 1 -- 3 axillary lymph nodes show tumor involvement, post-mastectomy radiation must be carried out if the patient has an increased risk of recurrence (e.g. HER2-positive, triple-negative, G3, L1, Ki-67 \> 30%, \> 25% of excised lymph nodes show tumor involvement; age ≤ 45 years with additional risk factors such as medial tumor location or tumor size \> 2 cm, or ER-negative).\               
          c) PMRT should not be carried out if 1 -- 3 axillary lymph nodes show tumor involvement and the tumor has a low risk of local recurrence (pT1, G1, ER-positive, HER2-negative, at least 3 characteristics must apply).\                                                                                                                                                                                       
          d) For all other patients with 1 -- 3 axillary lymph nodes with tumor involvement, the individual indication for treatment must be decided on by an interdisciplinary board.                                                                                                                                                                                                                                  

  4.42.   After primary (neoadjuvant) systemic therapy, the indication for post-mastectomy radiotherapy must be based on the clinical staging prior to treatment; for pCR (ypT0 and ypN0) the indication for treatment must be decided on by an interdisciplinary tumor board and depends on the patientʼs individual risk profile.                                                                         A     1a    [@R6464630-80] ,  [@R6464630-81] ,  [@R6464630-82] ,  [@R6464630-83]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Pretreatment                Post-treatment               RT-BCT ^1^   PMRT ^2^                   RT-LAW ^3^
  --------------------------- ---------------------------- ------------ -------------------------- ------------
  locally advanced            pCR/no pCR                   yes          Yes                        yes
  cT1/2 cN1+                  ypT1+ o. ypN1+ (no pCR)      yes          yes                        yes
  cT1/2 cN1+                  ypT0/is ypN0 (SLNE ≥ 3 LN)   yes          cases with high risk ^4^   
  cT1/2 cN0 (US obligatory)   ypT0/is ypN0 (SLNE ≥ 3 LN)   yes          no                         no

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                                                                                                     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                     EG    LoE                                                                                                                          Sources
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  4.43.                                                                                                                                                                                                                                                                                   Adjuvant irradiation of regional lymph drainage areas improves disease-free survival and overall survival rates in a subgroup of patients.                                                                                                                                                                                                                                                            1a                                                                                                                           [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]

  4.44.                                                                                                                                                                                                                                                                                   a\) Irradiation of the supra-/infraclavicular lymph nodes may be an option for patients with pN0 or pN1mi stage disease under the following circumstances if all of the following conditions are met:premenopausal and central or medial tumor location and G2--3 and ER/PgR-negative.                                                                                                          0     2a/2b                                                                                                                        [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]

  b\) Irradiation of the supra-/infraclavicular lymph nodes should be carried out in patients with 1 -- 3 affected lymph nodes in the following circumstances:central or medial location and (G2--3 or ER/PgR-negative)premenopausal, lateral location and (G2--3 or ER/PgR-negative)     B                                                                                                                                                                                                                                                                                                                                                                                               2a    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   

  c\) Irradiation of the supra-/infraclavicular lymph nodes must be generally carried out in all patients with \> 3 affected axillary lymph nodes.                                                                                                                                        A                                                                                                                                                                                                                                                                                                                                                                                               2a    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   

  4.45.                                                                                                                                                                                                                                                                                   a\) Irradiation of the internal thoracic artery lymph nodes may be carried out in patients without or with minimal axillary involvement (pN0 or pN1mi) in the following circumstances:premenopausal and central or medial location and G2--3 and ER/PgR-negative                                                                                                                                0     2b                                                                                                                           [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]

  b\) Irradiation of the internal thoracic artery lymph nodes should be carried out in patients with 1 -- 3 affected lymph nodes in the following circumstances:central or medial location and (G2--3 or ER/PgR-negative)premenopausal, lateral location and (G2--3 or ER/PgR-negative)   B                                                                                                                                                                                                                                                                                                                                                                                               2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]                                       

  c\) Irradiation of the internal thoracic artery lymph nodes should be carried out in patients with \> 3 affected axillary lymph nodes in the following circumstances:G2--3 or ER/PgR-negative                                                                                           B                                                                                                                                                                                                                                                                                                                                                                                               2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]                                       

  d\) If tumor involvement of the internal thoracic artery lymph nodes is confirmed, they should be treated with radiotherapy.                                                                                                                                                            B                                                                                                                                                                                                                                                                                                                                                                                               2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   

  e\) If patients have an increased cardiac risk or are receiving treatment with trastuzumab, the decision whether or not to irradiate the internal thoracic artery lymph nodes must be made on an individual basis by an interdisciplinary tumor board.                                  A                                                                                                                                                                                                                                                                                                                                                                                               4     [@R6464630-91] ,  [@R6464630-92]                                                                                             

  4.46.                                                                                                                                                                                                                                                                                   Expanded axillary radiation may be used to treat patients with 1 -- 2 affected axillary sentinel lymph nodes if no axillary dissection is carried out or if the interdisciplinary tumor board agrees that no further local axillary therapy should be carried out (analogous to ACOSOG Z0011). The decision about the appropriate approach must be taken by an interdisciplinary tumor board.   0/A   2b                                                                                                                           [@R6464630-35] ,  [@R6464630-93] ,  [@R6464630-94] ,  [@R6464630-95]

  4.47.                                                                                                                                                                                                                                                                                   Radiotherapy of lymph drainage areas should be administered in standard fractions (5 × week 1.8 to 2.0 Gy, total dose: approx. 50 Gy over a period of approx. 5 -- 6 weeks) or in hypofractionated doses (total dose: approx. 40 Gy in approx. 15 -- 16 fractions over a period of approx. 3 to 5 weeks).                                                                                       EC                                                                                                                                 

  4.48.                                                                                                                                                                                                                                                                                   Treatment of patients with primary inoperable or inflammatory cancer must consist of primary systemic therapy followed by surgery and postoperative radiotherapy or, if the cancer continues to be inoperable, radiotherapy alone or preoperative radiotherapy.                                                                                                                                 A     1b                                                                                                                           [@R6464630-96] ,  [@R6464630-97]

  4.49.                                                                                                                                                                                                                                                                                   a\) Postoperative chemotherapy and radiotherapy must be administered sequentially.\                                                                                                                                                                                                                                                                                                             A     1b                                                                                                                           [@R6464630-98] ,  [@R6464630-99] ,  [@R6464630-100] ,  [@R6464630-101]
                                                                                                                                                                                                                                                                                          Note: No specific sequence (chemotherapy first or radiotherapy first) has been confirmed as superior. The sequence of chemotherapy followed by radiotherapy is the established sequence in clinical practice.                                                                                                                                                                                                                                                                                                                      

  b\) If only RT is administered, treatment with RT should commence within a period of 8 weeks postoperatively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 [@R6464630-102] ,  [@R6464630-103]                                                                                           

  c\) Adjuvant endocrine therapy can be started independently of any radiotherapy. (1a)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        [@R6464630-91] ,  [@R6464630-92] ,  [@R6464630-104] ,  [@R6464630-105]                                                       
  Therapy with trastuzumab may be continued during radiotherapy. If the patient is receiving simultaneous irradiation of the internal thoracic artery lymph nodes, the appropriate approach must be decided on by an interdisciplinary tumor board. (4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 1.3  Systemic adjuvant therapy (endocrine therapy, chemotherapy, antibody therapy)

#### 1.3.1  Choice of adjuvant therapy and classification of risk

The 2009 St. Gallen Recommendations have pointed out the significance of endocrine sensitivity and the 2011 Recommendations have highlighted the importance of molecular subtypes as the decisive criteria whether adjuvant chemotherapy is indicated or not [@R6464630-106] . The markers ER, PgR, HER2 and Ki-67, which are identified by immunohistochemistry, are considered surrogate parameters for different molecular subtypes [@R6464630-106] . ER-positive and/or PgR-positive, HER2-negative tumors with low proliferation rates are classified as luminal A; if the proliferation rates are high, they are classified as luminal B. It should be noted that there is currently no validated threshold value for Ki-67 (e.g. for classifying a tumor as luminal A vs. luminal B or to confirm the decision for/against adjuvant chemotherapy).

Indications for adjuvant chemotherapy:

-   simultaneous anti-HER2 therapy with trastuzumab over a period of 1 year combined with (neo-) adjuvant chemotherapy is the standard approach for HER2-positive tumors

-   non-endocrine-sensitive tumors (ER- and PgR-negative)

-   tumors which may not be endocrine-sensitive

-   node-positive tumors (studies are currently being carried out to evaluate whether patients with low numbers of affected lymph nodes \[1 -- 3 affected LN\] and favorable tumor biology \[luminal A\] may not need adjuvant chemotherapy)

-   G III

-   young age at onset (\< 35 years)

Chemotherapy is always indicated if the individual expected benefit is higher than potential side effects and long-term negative effects. This requires careful, in-depth counselling and discussions with the patient, particularly if the expected benefit is minimal.

#### 1.3.2  Endocrine therapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                                                                                                                                                                                      Recommendations/ Statements                                                                                                                                                              EG                       LoE                                                                                                            Sources
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  4.50.                                                                                                                                                                                                                                                                                                                                                                    a\) Patients with estrogen and/or progesterone receptor-positive\* invasive tumors must receive endocrine therapy.                                                                       A                        1a                                                                                                             [@R6464630-30] ,  [@R6464630-107] ,  [@R6464630-108] ,  [@R6464630-109] ,  [@R6464630-110]

  b\) Endocrine therapy must only be started after chemotherapy has been completed but it can be administered in parallel to radiotherapy.                                                                                                                                                                                                                                 A                                                                                                                                                                                        1a                       [@R6464630-30] ,  [@R6464630-45] ,  [@R6464630-107] ,  [@R6464630-108] ,  [@R6464630-109] ,  [@R6464630-110]   

  4.51.                                                                                                                                                                                                                                                                                                                                                                    After 5 years of tamoxifen the decision whether or not to continue endocrine therapy must be re-evaluated in every patient with ER+ breast cancer.\                                      A/B                      Adapt. from guide-line                                                                                         [@R6464630-111]
                                                                                                                                                                                                                                                                                                                                                                           When considering whether or not to continue endocrine therapy, the risk of recurrence and the therapy-related side effects (toxicity, decreased adherence) should be weighed up.\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                           The patientʼs current menopausal status must be taken into account when selecting the appropriate endocrine therapy.                                                                                                                                                                                                             

  4.52.                                                                                                                                                                                                                                                                                                                                                                    Premenopausal patients must receive tamoxifen therapy for at least 5 years.\                                                                                                             A                        1a                                                                                                             [@R6464630-107] ,  [@R6464630-108] ,  [@R6464630-112] ,  [@R6464630-113] ,  [@R6464630-114]
                                                                                                                                                                                                                                                                                                                                                                           Antiestrogen therapy with tamoxifen 20 mg per day must be administered for a period of 5 -- 10 years depending on the risk of recurrence or until recurrence occurs.\                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                           Whether or not expanded therapy is indicated depends on the risk of recurrence and the patientʼs wishes.                                                                                                                                                                                                                         

  4.53.                                                                                                                                                                                                                                                                                                                                                                    a\) High-risk patients with ER+ breast cancer who are still premenopausal after completing chemotherapy may be treated with an aromatase inhibitor after suppressing ovarian function.   EC                                                                                                                                      

  b\) Suppression of ovarian function alone can be considered in premenopausal women with ER+ breast cancer who cannot receive tamoxifen or do not want to be treated with tamoxifen; suppression can be achieved either by administering a GnRHa or by oophorectomy.                                                                                                      EC                                                                                                                                                                                                                                                                                                                               

  c\) Suppression of ovarian function (by GnRHa or bilateral oophorectomy) in addition to tamoxifen or an aromatase inhibitor must only be considered in patients with a high risk of recurrence who are premenopausal after receiving adjuvant chemotherapy. Suppression of ovarian function is mandatory when treatment consists of administering aromatase inhibitor.   A                                                                                                                                                                                        Adapt. from guide-line   [@R6464630-115]                                                                                                

  4.54.                                                                                                                                                                                                                                                                                                                                                                    Adjuvant endocrine therapy for postmenopausal patients with ER+ breast cancer should include an aromatase inhibitor.                                                                     B                        1b                                                                                                             [@R6464630-115]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.3.3  Adjuvant chemotherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                        EG   LoE                                                                                                              Sources
  --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  4.55.                                                                                                                                   a\) Adjuvant chemotherapy is indicated for:\                                                                                                                                                                                                                                                                                                       B    1a                                                                                                               [@R6464630-4] ,  [@R6464630-11] ,  [@R6464630-116] ,  [@R6464630-117] ,  [@R6464630-118] ,  [@R6464630-119]
                                                                                                                                          HER2-positive tumors (from pT1b, N0; pT1a, N0 if additional risks are present: e.g., G3, ER/PR-negative, high Ki67 levels)Triple-negative tumors (ER- and PgR-negative, HER2-negative)Luminal-B tumors with a high risk of recurrence (high Ki-67 levels, G3, high-risk multigene assay, young age at onset, lymph nodes show tumor involvement)                                                                                                                         

  b\) Chemotherapy must be administered in the recommended doses.\                                                                        A                                                                                                                                                                                                                                                                                                                                                  1a   [@R6464630-118] ,  [@R6464630-120] ,  [@R6464630-121] ,  [@R6464630-122] ,  [@R6464630-123] ,  [@R6464630-124]   
  Under-dosing or reducing the number of cycles risks reducing the efficacy of chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  4.56.                                                                                                                                   Cytostatic agents may be administered simultaneously or sequentially (according to the evidence-based protocols).\                                                                                                                                                                                                                                 B    1b.                                                                                                              [@R6464630-125] ,  [@R6464630-126] ,  [@R6464630-127] ,  [@R6464630-128] ,  [@R6464630-129] ,  [@R6464630-130]
                                                                                                                                          Dose-dense therapies should be used to treated suitable patients with a high tumor-related risk of mortality.                                                                                                                                                                                                                                                                                                                                                            

  4.57.                                                                                                                                   Adjuvant chemotherapy should include a taxane and an anthracycline.                                                                                                                                                                                                                                                                                B    1a                                                                                                               [@R6464630-116] ,  [@R6464630-126] ,  [@R6464630-131] ,  [@R6464630-132] ,  [@R6464630-133] ,  [@R6464630-134] ,  [@R6464630-135] ,  [@R6464630-136] ,  [@R6464630-137] ,  [@R6464630-138] ,  [@R6464630-139]

  6 cycles of TC (docetaxel/cyclophosphamide) may be an alternative in patients with moderate clinical risk (≤ 3 affected lymph nodes).   0                                                                                                                                                                                                                                                                                                                                                  1a                                                                                                                    

  Standard adjuvant chemotherapy must take 18 -- 24 weeks.                                                                                A                                                                                                                                                                                                                                                                                                                                                  1a                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.3.4  Neoadjuvant therapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                                                                                                                 Recommendations/ Statements                                                                                                                                                                                                                                                         EG   LoE                                                                        Sources
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- -------------------------------------------------------------------------- -------------------------------------------------------
  4.58.                                                                                                                                                                                                                                                                                               a\) Neoadjuvant (primary, preoperative) systemic therapy is considered the standard treatment for patients with locally advanced, primary inoperable or inflammatory breast cancer in the context of a multimodal therapy concept.                                                  EC                                                                              

  b\) Neoadjuvant systemic therapy should be preferred if the same postoperative adjuvant chemotherapy is indicated.                                                                                                                                                                                  EC                                                                                                                                                                                                                                                                                                                                                                  

  4.59.                                                                                                                                                                                                                                                                                               a\) If chemotherapy is indicated, it can be administered prior to surgery (neoadjuvant) or after surgery (adjuvant). Both approaches are equivalent with regard to overall survival.\                                                                                                    1a                                                                         [@R6464630-140] ,  [@R6464630-141] ,  [@R6464630-142]
                                                                                                                                                                                                                                                                                                      Neoadjuvant therapy may lead to a higher rate of breast-conserving therapies.                                                                                                                                                                                                                                                                                       

  b\) The effect (pathohistological remission) is greatest for hormone receptor-negative cancers.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1a   [@R6464630-140] ,  [@R6464630-141] ,  [@R6464630-143] ,  [@R6464630-144]   

  c\) Resection within the new tumor margins is possible if R0 resection can be achieved.                                                                                                                                                                                                             EC                                                                                                                                                                                                                                                                                                                                                                  

  4.60.                                                                                                                                                                                                                                                                                               a\) Postmenopausal patients with endocrine-sensitive breast cancer, for whom surgery or chemotherapy is not possible or who do not want surgery or chemotherapy, may be treated with primary endocrine therapy.                                                                     EC                                                                              

  b\) Neoadjuvant endocrine therapy is not a standard therapy; neoadjuvant endocrine therapy may be considered in special situations (inoperable cancer, multiple morbidities).                                                                                                                       EC                                                                                                                                                                                                                                                                                                                                                                  

  4.61.                                                                                                                                                                                                                                                                                               a\) If a neoadjuvant chemotherapy combination is used, it should include an anthracycline and a taxane. Preoperative therapy should take 18 -- 24 weeks.\                                                                                                                           EC                                                                              
                                                                                                                                                                                                                                                                                                      HER2-positive tumors for which neoadjuvant chemotherapy is indicated should be treated with trastuzumab. High-risk (clinical/sonographic findings or N+ on punch biopsy, tumor size \> 2 cm) HER2-positive patients should additionally receive pertuzumab.                                                                                                         

  b\) Platinum salts increase the complete remission rate (pCR rate) in patients with triple-negative breast cancer (TNBC) irrespective of their BRCA status. The benefit for progression-free survival (PFS) and overall survival has not yet been conclusively confirmed. The toxicity is higher.   EC                                                                                                                                                                                                                                                                                                                                                                  

  4.62.                                                                                                                                                                                                                                                                                               If anthracycline-taxane-based neoadjuvant chemotherapy is adequate, no additional adjuvant chemotherapy is recommended for tumor residues in the breast and/or lymph nodes. Post-neoadjuvant chemotherapy treatment should only be carried out in the context of clinical trials.   EC                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.3.5  Antibody therapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                             Recommendations/ Statements                                                                                                                                                                                                                                                                                  EG   LoE               Sources
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- ----------------- ----------------------------------------------------
  4.63.                                                                                                                                                                                                           a\) Patients with HER2-overexpressing tumors with a diameter ≥ 1 cm (immunohistochemical score 3+ and/or ISH-positive) must receive (neo) adjuvant treatment with an anthracycline followed by a taxane in combination with trastuzumab. Trastuzumab must be administered over a total period of one year.   A    1b                [@R6464630-16] ,  [@R6464630-29] ,  [@R6464630-30]

  b\) Adjuvant treatment with trastuzumab should preferably be started at the same time as the taxane phase of adjuvant chemotherapy.                                                                             B                                                                                                                                                                                                                                                                                                            2a   [@R6464630-145]   

  c\) If chemotherapy is indicated to treat HER2+ tumors ≤ 5 mm, trastuzumab should be additionally administered.\                                                                                                EC                                                                                                                                                                                                                                                                                                                                  
  Six cycles of TCH (docetaxel, carboplatin, trastuzumab) every 3 weeks may also be recommended as an adjuvant treatment. The cardiotoxicity of this approach is lower than after treatment with anthracyclines                                                                                                                                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 1.3.6  Bone-targeted therapy

##### 1.3.6.1  Therapy and prevention of cancer treatment-induced bone loss

The risk of bone density loss with destruction of bone structure and the risk of therapy-related osteoporosis followed by an increased risk of fractures is significantly higher in patients with malignant disease [@R6464630-146] . Apart from such commonly reported changes as immobilization and changes in lifestyle (e.g. discontinuation of estrogen therapy), it is primarily drug therapies that are responsible for osseous changes. Supportive therapies (e.g. cortisone preparations) are as likely to damage bones as cytotoxic or endocrine drugs. This issue is becoming increasingly important following the high curative rates for many solid tumors, particularly for breast cancer.

In premenopausal women with hormone receptor-positive breast cancer, ovarian function suppression (e.g. using GnRH analogs) alone or in combination with tamoxifen or an aromatase inhibitor and treatment with tamoxifen alone leads to a loss of bone density and an increased incidence of osteoporosis compared to healthy control populations [@R6464630-147] ,  [@R6464630-148] ,  [@R6464630-149] . The combination of ovarian function suppression with an aromatase inhibitor led to the greatest decrease in bone density [@R6464630-147] .

In postmenopausal women, treatment with aromatase inhibitors also leads to a loss of bone density and an increased incidence of fractures compared to women treated with tamoxifen [@R6464630-150] , [@R6464630-151] , [@R6464630-152] , [@R6464630-153] .

Chemotherapies can also result in a significant loss of bone density [@R6464630-154] ,  [@R6464630-155] .

The indication for preventive treatment depends on the patientʼs gender, age and bone density and should take the patientʼs history and lifestyle into account. Primary prevention of cancer therapy-induced bone loss should be considered if patients present with a special combination of risks [@R6464630-156] ,  [@R6464630-157] . These include advanced age, low body mass index, nicotine abuse, therapy with aromatase inhibitors, familial disposition, long-term cortisone therapy, immobility, endocrine disease, medication (Confederation of German-speaking Scientific Osteology Society, <http://www.dv-osteologie.org> ) [@R6464630-158] .

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                                                                                                              EG   LoE   Sources
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- --------------------------------------------------------------------------
  4.64.   In patients with an increased familial or cancer therapy-related risk of bone loss, bone density measurements should be carried out prior to starting treatment.\                                                                                        EC         
          Bone density measurements should be repeated at regular intervals depending on the results and the presence of additional risk factors.                                                                                                                             

  4.65.   Depending on the patientʼs individual combination of risk factors for developing osteoporosis, preventive treatment should be considered to prevent cancer therapy-induced osteoporosis ( <http://www.dv-osteologie.org> ; ESMO bone health guidance).   EC         

  4.66.   Osteoprotective therapy should be considered for premenopausal patients receiving GnRH and/or TAM and postmenopausal patients receiving treatment with AI.                                                                                               B    1b    [@R6464630-147] ,  [@R6464630-150] ,  [@R6464630-152] ,  [@R6464630-158]

  4.67.   Hormone therapy with estrogens should not be used to prevent cancer therapy-related osteoporosis in breast cancer patients as an increased rate of recurrence cannot be excluded, particularly in patients with hormone receptor-positive disease.       B    1a    [@R6464630-159]

  4.68.   In addition to these general recommendations, bisphosphonates or denosumab may be used for primary prevention of cancer therapy-induced bone loss.                                                                                                       EC         

  4.69.   A reduced risk of fractures associated with endocrine therapy has only been clearly confirmed for denosumab but has not yet been confirmed for bisphosphonates.                                                                                          A    1     [@R6464630-150]

  4.70.   Bone-targeted therapy to prevent therapy-related osteoporosis should be carried out for the duration of endocrine therapy.                                                                                                                               EC         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**1.3.6.1.1  Therapy for cancer therapy-induced osteoporosis**

  No.     Recommendations/ Statements                                                                                                  EG
  ------- ---------------------------------------------------------------------------------------------------------------------------- ----
  4.71.   It is important to exclude bone metastasis if a bone fracture occurs which was not caused by sufficiently powerful trauma.   EC

##### 1.3.6.2  Adjuvant therapy to improve bone metastasis-free survival and overall survival

According to the "seed and soil" hypothesis, luminal breast cancer cells are particularly prone to metastasize in bone where they are then detected in the form of disseminated tumor cells [@R6464630-160] ,  [@R6464630-161] ,  [@R6464630-162] . Bisphosphonates and probably also denosumab appear to have a therapeutic effect with regard to the persistence of these cells and thus on the incidence of secondary bone metastasis [@R6464630-163] .

Two meta-analyses evaluated studies on the adjuvant use of different bisphosphonates. Ben-Aharon and colleagues found a positive effect on survival in postmenopausal patients with breast cancer (HR 0.81 \[0.69 -- 0.95\]) [@R6464630-164] . In their meta-analysis, Coleman and colleagues reported a significant positive effect on bone metastasis-free survival of 34% and on overall survival of 17% for postmenopausal patients (including premenopausal patients with ovarian function suppression from GnRH analogs; ABCSG-12) [@R6464630-165] .

The meta-analyses found no significant benefit for premenopausal patients (without ovarian function suppression from GnRH analogs) with regard to disease-free survival, bone metastasis-free survival and overall survival. No effect on prognosis was detected in an evaluation of a secondary endpoint carried out in a subpopulation of premenopausal patients (the majority of whom did not have suppression of ovarian function), despite the high therapy density at the start of treatment (AZURE trial [@R6464630-158] ).

To date, no bisphosphonate has been approved for use in adjuvant therapy in the European Union, meaning that treatment can currently only be carried out as an off-label use.

  No.     Recommendations/ Statements                                                                                                                                                                                                  EG   LoE   Sources
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- -------------------------------------------------------
  4.72.   Adjuvant bisphosphonate therapy prolongs bone metastasis-free survival and overall survival in postmenopausal patients with breast cancer and in premenopausal patients with ovarian function suppression (off-label use).   A    1     [@R6464630-164] ,  [@R6464630-165]
  4.73.   It is currently not possible to recommend the adjuvant use of bisphosphonates or denosumab for premenopausal patients with suppression of ovarian function.                                                                  0    1b    [@R6464630-158] ,  [@R6464630-164] ,  [@R6464630-165]

##### 1.3.6.3  Bone-targeted therapy for patients with bone metastasis

The most common metastases of breast cancer occur in bone marrow. Luminal tumors have a particular affinity to the skeleton. The most common complications of bone metastases are pain, pathological fractures, vertebral compression syndrome, and hypercalcemia [@R6464630-166] . If the aforementioned symptoms (with the exception of pain) occur, then morbidity is significantly increased. A number of different measures can be initiated to prevent these serious complications.

The interdisciplinary AWMF S3 guideline 032-054OL "Supportive Therapy for Oncology Patients" provides a detailed discussion of the diagnosis and therapy of bone metastases [@R6464630-167] ).

  No.     Recommendations/ Statements                                                                                                                                                              EG
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  4.74.   Patients must go to the dentist before starting adjuvant osteoprotecttive therapy. The Recommendations of the S3 guideline on "Antiresorptive drug-related necrosis of the jaw" apply.   EC

#### 1.3.7  Lifestyle factors which can be influenced

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                  EG   LoE                      Sources
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ------------------------ ----------------------------------------------------------------------------------------------------------------
  4.75.   Patients must be motivated to carry out physical exercise and to normalize their body weight (if their BMI is high). Patients should receive support and assistance. It is particularly recommended that patients:\                                                                                                          A    2a/1a                    [@R6464630-168] ,  [@R6464630-169] ,  [@R6464630-170] ,  [@R6464630-171]
          a) avoid physical inactivity and return to normal daily activities as early as possible after diagnosis (LoE 2a)\                                                                                                                                                                                                                                          
          b) work towards achieving the goal of 150 minutes of moderate or 75 minutes of strenuous physical activity per week (LoE 1a)                                                                                                                                                                                                                               

  4.76.   Patients should be offered weight training programs, particularly when they are undergoing chemotherapy and hormone therapy.                                                                                                                                                                                                 B    1b                       [@R6464630-172] ,  [@R6464630-173] ,  [@R6464630-174] ,  [@R6464630-175]

  4.77.   Patients should be advised and taught to do regular sports activities and physical exercise to treat breast cancer-associated fatigue.                                                                                                                                                                                       B    1a                       [@R6464630-176] ,  [@R6464630-177] ,  [@R6464630-178] ,  [@R6464630-179]

  4.78.   If manifest chemotherapy-induced polyneuropathy is present, patients should have exercise therapy to improve functionality.\                                                                                                                                                                                                 B    1a/2a                    [@R6464630-173] ,  [@R6464630-174] ,  [@R6464630-180] ,  [@R6464630-181]
          This may include:balance exercisessensorimotor trainingcoordination trainingvibration trainingfine motor skills training                                                                                                                                                                                                                                   

  4.79.   Patients with lymphedema after surgery for breast cancer must be started on monitored, gradually progressive weight training to treat lymphedema.                                                                                                                                                                            B    1b                       [@R6464630-182] ,  [@R6464630-183] ,  [@R6464630-184] ,  [@R6464630-185] ,  [@R6464630-186] ,  [@R6464630-187]

  4.80.   Patients should be counselled (a) about achieving and maintaining a healthy body weight, and (b) if they are overweight or obese, about how to limit their consumption of highly-calorific food and drinks and how to increase their physical activity to promote moderate weight loss and maintain it over the long-term.   A    Adapt. From guide-line   [@R6464630-188]

  4.81.   Patients should be counselled on how to achieve and adhere to a nutritional program rich in vegetables, fruit, wholegrain and pulses which contains few saturated fats and only limited alcohol consumption.                                                                                                                 A    Adapt. from guide-line   [@R6464630-188]

  4.82.   Patients must receive counselling not to smoke; if necessary, smokers must be recommended smoking cessation programs.                                                                                                                                                                                                        A    2a                       [@R6464630-188]

  4.83.   To prevent late recurrence (\> 5 years after primary diagnosis), patients with receptor-positive disease should avoid a daily alcohol consumption of \> 12 g pure alcohol.                                                                                                                                                   B    2a                       [@R6464630-189]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 1.4  Breast cancer during pregnancy and lactation, pregnancy after breast cancer, fertility preservation

#### 1.4.1  Pregnancy after breast cancer

  No.                                                                                                                                                                         Recommendations/ Statements                                                                                                                                                                                                                                                                        EG   LoE               Sources
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----------------- -------------------------------------------------------
  7.1.                                                                                                                                                                        Patients who have had breast cancer must not be counselled against becoming pregnant. This applies irrespective of their hormone status.                                                                                                                                                           A    3a                [@R6464630-190] ,  [@R6464630-191]
  7.2.                                                                                                                                                                        a\) The interval until becoming pregnant after breast cancer is not correlated with a poorer prognosis.                                                                                                                                                                                            A    3a                [@R6464630-190]
  b\) The risk of recurrence depends on the tumor biology and the stage of disease. This must be discussed during counselling for any subsequent pregnancy.                   EC                                                                                                                                                                                                                                                                                                                        
  7.3.                                                                                                                                                                        The longer the endocrine therapy, the better the chances for a cure (see Chapter 4.7.2 Endocrine therapy). If the patient wished to become pregnant before completing endocrine therapy, then endocrine therapy should be continued after the patient has given birth and stopped breastfeeding.   EC                     
  7.4.                                                                                                                                                                        a\) Patients can try to become pregnant after breast cancer with the help of reproductive medical procedures.                                                                                                                                                                                      0    4                 [@R6464630-192] ,  [@R6464630-193] ,  [@R6464630-194]
  b\) The chances of success (i.e. an intact pregnancy or baby) are lower for breast cancer patients when autologous eggs are used compared to women without breast cancer.                                                                                                                                                                                                                                                                                                      2c   [@R6464630-195]   

#### 1.4.2  Breast cancer during pregnancy

  No.                                                                                                                        Recommendations/ Statements                                                                                                                                                                                              EG   LoE
  -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- ---------------------------------------------------------------------------------------------
  7.5.                                                                                                                       a\) Treatment (systemic therapy, surgery, RT) for breast cancer (in pregnant patients) during pregnancy must be as similar as possible to treatment administered to younger, non-pregnant patients with breast cancer.   EC   
  b\) Standard chemotherapy with anthracyclines and taxanes may be administered in the 2nd and 3rd trimester of pregnancy.   0                                                                                                                                                                                                                        2b   [@R6464630-196] ,  [@R6464630-197] ,  [@R6464630-198] ,  [@R6464630-199] ,  [@R6464630-200]
  c\) Anti-HER2 therapy must not be administered during pregnancy.                                                           A                                                                                                                                                                                                                        3a   [@R6464630-196] ,  [@R6464630-197] ,  [@R6464630-199]
  d\) Endocrine therapy must not be administered during pregnancy.                                                           EC                                                                                                                                                                                                                            
  e\) Surgery may be carried out in the same way as in non-pregnant patients.                                                EC                                                                                                                                                                                                                            

#### 1.4.3  Fertility preservation

  No.                                                                                                                                                          Recommendations/ Statements                                                                                                                               EG   LoE
  ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- ---- -----------------------------------------------------------------------------------------------------------------------------------
  7.6.                                                                                                                                                         a\) Patients of childbearing age with breast cancer must receive counselling about fertility and preserving fertility before starting cancer treatment.   EC   
  b\) The administration of a GnRH analog before starting chemotherapy may be considered in all women who wish to preserve their ovarian function/fertility.   0                                                                                                                                                         1b   [@R6464630-200] ,  [@R6464630-201] ,  [@R6464630-202] ,  [@R6464630-203] ,  [@R6464630-204] ,  [@R6464630-205] ,  [@R6464630-206]

### 1.5  Breast cancer in older patients

#### 1.5.1  General comments

  No.    Recommendations/ Statements                                                                                                                                                                                                                       EG
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  8.1.   Therapeutic decisions for older patients should be based on current standard recommendations but also take account of the patientʼs biological age, life-expectancy and preferences; the benefits and risks of such therapy must be weighed up.   EC

#### 1.5.2  Geriatric patients

  No.    Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                            EG   LoE   Sources
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- ----- --------------------------------------------------------------------------------------------
  8.2.   Patients who are older than 75 years should have a geriatric assessment or screening using a geriatric assessment algorithm, particularly if chemotherapy or surgery requiring a general anesthetic is planned, with the aim of improving therapy adherence, tolerance of chemotherapy and possibly survival.                                                                                          B    2a    [@R6464630-207] ,  [@R6464630-208] ,  [@R6464630-209] ,  [@R6464630-210]
  8.3.   Geriatric assessment and management should cover therapy-relevant geriatric domains (particularly functionality-related parameters such as activities of daily living, mobility, cognition, falls, and morbidity-related parameters such as multiple medication, nutrition, fatigue, and number of comorbidities) in order to adapt the choice of therapy accordingly and start supportive measures.   B    2a    [@R6464630-30] ,  [@R6464630-211] ,  [@R6464630-212] ,  [@R6464630-213] ,  [@R6464630-214]

#### 1.5.3  Local therapy

  No.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Recommendations/ Statements                                                                                                        EG   LoE
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---- -----------------
  8.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      a\) Surgical therapy to treat older patients is basically no different from the surgical therapy used to treat younger patients.   EC   
  b\) Patients with ER/PR-positive breast cancer: primary endocrine therapy should be started if surgery is not carried out because of the patientʼs frailty (e.g., comorbidities and higher anesthetic risk) or because the patient rejects surgery. When deciding on the appropriate therapy, any drug-related specific side effects, particularly the risk of thrombosis/embolism (tamoxifen) and the risk of bone fractures (aromatase inhibitors), must be taken into consideration.   B                                                                                                                                  1b   [@R6464630-215]
  c\) Patients with ER- and PR-negative breast cancer: if surgery under general anesthesia is not carried out because of the patientʼs frailty (e.g. comorbidities and increased surgical risk) or because the patient rejects surgery, surgery under local anesthesia, primary radiotherapy or purely palliative medical treatment may be considered.                                                                                                                                      EC                                                                                                                                      

#### 1.5.4  Adjuvant endocrine therapy

  No.    Recommendations/ Statements                                                                                                                                                                                                                                                    EG   LoE   Sources
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- ----- ------------------------------------
  8.5.   Endocrine therapy is recommended for patients with hormone receptor-positive disease. Endocrine therapy may be dispensed with in individual cases (i.e., when treating patients with very low-grade tumors or very favorable tumor biology or if the patient is very frail).   0    2b    [@R6464630-213] ,  [@R6464630-216]

#### 1.5.5  Adjuvant chemotherapy

  No.    Recommendations/ Statements                                                                                                                                                                                                   EG   LoE   Sources
  ------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  8.6.   As patients become frailer with increasing age, their reduced physical reserves and changes in their pharmacokinetics may lower the tolerability of chemotherapy and increase the rate of side effects requiring treatment.   EC         
  8.7.   Chemotherapy may be associated with a significant reduction in cognitive performance in older women aged \> 70 years.                                                                                                              2b    [@R6464630-217] ,  [@R6464630-218]
  8.8.   Preference should be given to anthracycline and/or taxane-based combinations or sequential regimens. The increased risk of cardiotoxicity and of MDS/AML associated with anthracyclines must be taken into consideration.     B    2a    [@R6464630-219] ,  [@R6464630-220] ,  [@R6464630-221] ,  [@R6464630-222] ,  [@R6464630-223] ,  [@R6464630-224] ,  [@R6464630-225] ,  [@R6464630-226] ,  [@R6464630-227]

#### 1.5.6  Anti-HER2 therapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                          EG   LoE     Sources
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ------- --------------------------------------------------------------------------
  8.10.   Treatment is analogous to the treatment administered to younger patients and consists of trastuzumab combined sequential anthracycline-taxane-based chemotherapy.\        EC/1b   [@R6464630-214] ,  [@R6464630-228] ,  [@R6464630-229] ,  [@R6464630-230]
          It is important to be aware of the increased risk of cardiotoxicity associated with this approach. (EC)\                                                                          
          An anthracycline-free combination consisting of carboplatin-docetaxel or docetaxel-cyclophosphamide may be used. (1b)                                                             

  8.11.   Paclitaxel administered weekly (over 12 weeks) with trastuzumab may be used to treat T1--2 (up to 3 cm) pN0 tumors.                                                  0    2b      [@R6464630-231] ,  [@R6464630-232]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 1.6  Breast cancer in men

Breast cancer in men should be diagnosed and treated by an interdisciplinary group of specialists. Because of the type of tumor biology and the similarities to breast cancer in women, specialists for gynecologic oncology must also be involved when treating breast cancer in men. An interdisciplinary cooperation between breast centers, gynecologists, urologists and andrologists is particularly advisable when treating sexual disorders caused by therapy with tamoxifen, men with BRCA mutations [@R6464630-233] who have an increased associated risk of prostate cancer, and men with breast cancer who must be treated for benign prostate syndrome [@R6464630-234] .

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                               EG
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  9.1.    a\) Patients must be encouraged to ask for medical counselling early on and provided with information about disease, particularly about symptoms and changes in the breast; they must be encouraged to monitor themselves.\                                                                                               EC
          b) If there is a suspicion of malignancy, the initial investigation must include taking the patientʼs history, clinical examination, mammography, and ultrasound examination of the breast and of the lymphatic drainage areas. There are no data on the diagnostic use of CM-MRI.\                                       
          c) If there are malignant findings in the breast and axilla, further examinations with staging/investigation into the extent and spread of disease must be carried out in accordance with the recommendations made for women in the same situation, although there are no data on the diagnostic use of CM-MRI.           

  9.2.    a\) The aim of surgery is complete resection of the tumor. Surgery should consist of a mastectomy. Breast-conserving surgery should be considered if the tumor is small enough.\                                                                                                                                          EC
          b) If the axilla are clinically unremarkable (cN0), sentinel lymph node resection must be carried out, with the same rules applying as for women.                                                                                                                                                                         

  9.3.    Irrespective of surgery, adjuvant radiotherapy of the thoracic wall and, if necessary, of the lymphatic drainage areas (the indications for this are the same as for women) must be carried out to treat large tumors (≥ 2 cm) and axillary lymph node involvement if the hormone receptor status is negative.            EC

  9.4.    When deciding whether adjuvant chemotherapy and antibody therapy (anti-HER2) are indicated, the same rules apply as for women and the same therapy must be carried out.                                                                                                                                                   EC

  9.5.    Patients with hormone receptor-positive breast cancer must receive adjuvant endocrine therapy with tamoxifen, usually over a period of 5 years. There are no data available about treatment for more than 5 years. It may be considered in individual cases in the same way it would be considered when treating women.   EC

  9.6.    a\) Metastatic disease should be treated according to the same rules as those used to treat women.\                                                                                                                                                                                                                       EC
          b) It is not clear whether aromatase inhibitors are sufficiently effective in men without suppression of testicular function. Aromatase inhibitors should therefore be administered together with suppression of testicular function.                                                                                     

  9.7.    Men with breast cancer should be offered the opportunity to participate in trials/be included in tumor registers.                                                                                                                                                                                                         EC

  9.8.    Genetic testing must be recommended to all men with breast cancer.                                                                                                                                                                                                                                                        EC

  9.9.    The follow-up regimen including imaging evaluations must be analogous to the approach used for women.                                                                                                                                                                                                                     EC

  9.10.   The patient should be provided with qualified and relevant gender-specific information (in print and online) by the professionals who treat them, and the patient should be helped to access the targeted support and information available from self-help groups.                                                        EC
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Table 5**  Risk factors for men to develop breast cancer.

  --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age                                                                                                       Unimodal age distribution; the highest incidence is in the 71st year of life
  Ethnicity                                                                                                 Increased risk for men of African or Caribbean descent, who usually also have an advanced stage of disease when they are first diagnosed
  Germline mutations                                                                                        If the patientʼs family has a positive history of germline mutations for both sexes, they have a 2.5-fold higher risk of disease; BRCA-2 mutations were confirmed in 4 -- 40% of all cases; RAD51B gene modifications increase the risk by 50%
  Endocrine causes                                                                                          Exposure to exogenous estrogen, e.g. hormone therapy for transsexuals, treatment of prostate cancer, professional exposure
  Increased endogenous estrogen synthesis: Klinefelter syndrome, obesity                                    
  Decreased levels of androgen: orchiectomy, undescended testicle, mumps orchitis, cirrhosis of the liver   
  Environment                                                                                               Lifestyle: obesity, lack of exercise, excessive consumption of alcohol
  Exposure to radiation: nuclear weapons, radiotherapy, diagnostic radiology                                
  Professional exposure: high temperatures, petroleum, exhaust gases                                        
  --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2  Therapy (Recurrence/Metastasis)
----------------------------------

### 2.1  Therapy for local/loco-regional recurrence

#### 2.1.1  Local (intramammary) recurrence

  No.                                                                                                                                                                                                                                                                                                        Recommendations/ Statements                                                                                                                                                                                                                                                                EG   LoE
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- --------------------------------------------------------------------------
  5.7.                                                                                                                                                                                                                                                                                                       a\) If there is a suspicion of loco-regional recurrence, the first step must be histological verification including repeat determination of ER, PR and HER2/neu status and complete re-staging to exclude metastasis and make it possible to plan an interdisciplinary therapy strategy.   EC   
  b\) The highest level of local tumor control in patients with intramammary recurrence (DCIS/invasive carcinoma) is achieved by secondary mastectomy.                                                                                                                                                       EC                                                                                                                                                                                                                                                                                              
  c\) If the initial situation is favorable (e.g. DCIS or invasive carcinoma with a lengthy recurrence-free interval and no skin involvement), then breast-conserving surgery can be carried out again after careful counselling of the patient.                                                             0                                                                                                                                                                                                                                                                                          4a   [@R6464630-235] ,  [@R6464630-236] ,  [@R6464630-237] ,  [@R6464630-238]
  d\) Prior to carrying out another breast-conserving surgery, the possibility of carrying out repeat radiotherapy (partial breast irradiation) should be investigated and discussed by an interdisciplinary tumor conference; if necessary, the patient should have an appointment with a radiotherapist.   EC                                                                                                                                                                                                                                                                                              
  e\) After breast-conserving surgery, the patient must be informed about the increased risk of repeat intramammary recurrence.                                                                                                                                                                              EC                                                                                                                                                                                                                                                                                              

#### 2.1.2  Local recurrence after mastectomy

  No.    Recommendations/ Statements                                                                                                                                                                                                                                                           EG
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.8.   Any isolated recurrence in the thoracic wall must be completely resected (R0) where possible. If the main site of recurrence is the ribs/intercostal muscles, the decision for therapy should be taken after interdisciplinary consultation with a specialist for thoracic surgery.   EC
  5.9.   Local therapy (surgical intervention, radiotherapy) may be considered for symptomatic local recurrence (e.g. ulceration, pain) to reduce symptoms, even if the patient has distant metastasis.                                                                                        EC

#### 2.1.3  Axillary lymph node recurrence

  No.     Recommendations/ Statements                                                                                                                                                                                                                                   EG
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.10.   In the event of axillary lymph node recurrence, local recurrence of disease should be controlled by repeat surgical axillary intervention, if need be with radiotherapy. Thoracic CT should be done preoperatively to identify the extent of LN metastasis.   EC

#### 2.1.4  Drug therapy

  No.     Recommendations/ Statements                                                                                                                     EG
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.11.   Systemic therapy after R0 resection of loco-regional recurrence must be considered to prolong the disease-free interval and overall survival.   EC

#### 2.1.5  Radiotherapy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Recommendations/ Statements                                                                                                                                     EG
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.12.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     a\) The question whether radiation is indicated after surgery for recurrence must be discussed and decided by an interdisciplinary tumor board.\                EC
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Postoperative radiotherapy should be carried out if no radiotherapy was carried out previously or if the local recurrence was not radically resected (R1--2).   

  b\) Palliative radiotherapy, if necessary in combination with chemotherapy, may be used to treat inoperable local recurrence and control symptoms.                                                                                                                                                                                                                                                                                                                                                        EC                                                                                                                                                              

  c\) If there is intramammary recurrence or recurrence in the thoracic wall after breast-conserving surgery (R0) or mastectomy (R0) which was not followed by radiotherapy, the decision whether adjuvant radiotherapy is indicated must follow the recommendations for primary disease.                                                                                                                                                                                                                   EC                                                                                                                                                              

  d\) If intramammary recurrence occurs after breast-conserving surgery (R0) followed by radiotherapy, the question whether adjuvant radiotherapy is indicated must be discussed by an interdisciplinary tumor board. Radiotherapy may be indicated for patients who did not experience serious late sequelae after the 1st radiotherapy.                                                                                                                                                                   EC                                                                                                                                                              

  e\) In the event of recurrence in the thoracic wall after mastectomy (R0) followed by radiotherapy, the question whether repeat radiotherapy is indicated for local control should be discussed by an interdisciplinary tumor board.                                                                                                                                                                                                                                                                      EC                                                                                                                                                              

  f\) In the event of recurrence in the thoracic wall after primary mastectomy without subsequent radiotherapy, adjuvant radiotherapy should be carried out after resection of the recurrence (R0) if additional risk factors are present (very small resection margins, rpN+, G3, lymph node invasion).                                                                                                                                                                                                    EC                                                                                                                                                              

  g\) In the event of recurrence in the thoracic wall after primary mastectomy without subsequent radiotherapy, the question whether repeat adjuvant radiotherapy is indicated after resection of the recurrence (R0) when additional risk factors are present (very small resection margins, rpN+, G3, lymph node invasion) should be discussed by an interdisciplinary tumor board. Radiotherapy may be indicated for patients who did not experience serious late sequelae after the 1st radiotherapy.   EC                                                                                                                                                              

  h\) Additional radiotherapy must be recommended if recurrence occurs in an area which was not previously irradiated, the recurrence was not completely resected (R1/R2), and the risk associated with complete surgical resection (R0) cannot be justified.                                                                                                                                                                                                                                               EC                                                                                                                                                              

  i\) An interdisciplinary tumor board must decide whether repeat radiotherapy is indicated when recurrence occurs after prior radiotherapy, the recurrence was not completely resected (R1/R2), and the risk associated with complete surgical resection (R0) cannot be justified.\                                                                                                                                                                                                                        EC                                                                                                                                                              
  Radiotherapy may be indicated in patients who did not experience serious late sequelae after the 1st radiotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 2.2  Distant metastases

#### 2.2.1  Systemic therapy for metastatic breast cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                                                                                      EG   LoE     Sources
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ------- ----------------------------------------------------------------------------------------------------------------------------------
  5.13.   Endocrine therapy ± targeted therapy is the therapy of choice for patients with hormone receptor-positive and HER2-negative cancer. Endocrine therapy is not indicated in patients for whom rapid remission is important to avoid pronounced symptoms in the affected organ.                                                                                                                                                                                     A    1b      [@R6464630-30] ,  [@R6464630-239] ,  [@R6464630-240] ,  [@R6464630-241] ,  [@R6464630-242] ,  [@R6464630-243]

  5.14.   Combined chemo-endocrine therapy is not recommended. Although this approach can increase the rate of remission, it also leads to increased toxicity without prolonging the progression-free interval or improving overall survival.                                                                                                                                                                                                                              A    1a      [@R6464630-244]

  5.15.   In premenopausal patients, suppression of ovarian function (with GnRH analogs, oophorectomy) combined with tamoxifen is the first-choice therapy if treatment with tamoxifen was not concluded less than 12 months previously. An alternative approach consisting of suppression of ovarian function followed by the same treatment as that recommended for postmenopausal women may be chosen, and endocrine therapy may be combined with CDK 4/6 inhibitors.   A    1b      [@R6464630-30] ,  [@R6464630-242] ,  [@R6464630-245] ,  [@R6464630-246]

  5.16.   Subsequently, ovarian suppression combined with an aromatase inhibitor or fulvestrant, if necessary in combination with palbociclib, can be used to treat premenopausal patients. As long as ovarian suppression is maintained, treatment may be administered in the same way as therapy for postmenopausal patients.                                                                                                                                            0    2c/EC   [@R6464630-247] ,  [@R6464630-248]

  5.17.   In postmenopausal patients, the first step of endocrine treatment for metastasis should consist of an aromatase inhibitor if adjuvant therapy consisted exclusively of tamoxifen or the patient did not receive adjuvant therapy. It is not possible to give a clear recommendation whether primary endocrine treatment should consist of a steroidal or a non-steroidal aromatase inhibitor. Letrozole may be combined with a CDK 4/6 inhibitor.                A    1a      [@R6464630-30] ,  [@R6464630-239] ,  [@R6464630-242] ,  [@R6464630-249] ,  [@R6464630-250] ,  [@R6464630-251] ,  [@R6464630-252]

  5.18.   Treatment with fulvestrant should be carried out after pretreatment with an aromatase inhibitor, although fulvestrant may also be used as a first-line therapy, particularly for patients who have not previously received endocrine therapy.                                                                                                                                                                                                                    EC           

  5.19.   No specific therapy sequence is recommended. A combination treatment consisting of letrozole or fulvestrant with a CDK 4/6 inhibitor represents an alternative to monotherapy.\                                                                                                                                                                                                                                                                                  EC           
          Follow-up therapy with exemestane and the mTOR inhibitor everolimus may be administered after anti-hormonal pretreatment with a non-steroidal aromatase inhibitor.\                                                                                                                                                                                                                                                                                                           
          Studies have shown that combination therapies prolonged progression-free survival but it has not yet been proven that they improve overall survival.                                                                                                                                                                                                                                                                                                                          

  5.20.   Depending on the patientʼs previous treatment, the next steps in the endocrine treatment sequence for postmenopausal patients consist of administration of antiestrogens, estrogen receptor antagonists, switching from a steroidal to a non-steroidal aromatase inhibitor or vice versa, or the use of high-dose progestogens.\                                                                                                                                 EC           
          If disease progression continues during treatment with a non-steroidal aromatase inhibitor, patients may treated with a combination of letrozole or fulvestrant with palbociclib or a combination of exemestane and everolimus.                                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### 2.2.2  Chemotherapy for metastatic breast cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.                                                                                                                                                                                                                                             Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          EG   LoE                                                                                                              Sources
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ---------------------------------------------------------------------------------------------------------------- ------------------------------------
  5.21.                                                                                                                                                                                                                                           Before starting chemotherapy, the patientʼs general condition, co-morbidities and previous therapies must be evaluated and her probable compliance with treatment must be assessed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  EC                                                                                                                    

  5.22.                                                                                                                                                                                                                                           Regular evaluations of toxicity (subjective and objective) must be carried out during therapy. Treatment doses and scheduled treatment intervals must follow generally accepted standard regimens or recently published therapy regimens. After determining suitable representative parameters (symptoms, tumor markers, imaging) prior to starting therapy, the effect of treatment must be evaluated at least every 6 -- 12 weeks according to clinical requirements. Over time, the intervals between imaging procedures can be extended for patients with sustained remission and a good clinical and laboratory assessment of disease status.   EC                                                                                                                    

  5.23.                                                                                                                                                                                                                                           Therapy should be discontinued if the patient has clinically relevant progression or toxicity is intolerable.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       EC                                                                                                                    
                                                                                                                                                                                                                                                  Patients should not change to a different chemotherapy regimen unless the patient has documented progression or toxicity is intolerable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  5.24.                                                                                                                                                                                                                                           a\) If chemotherapy is indicated, patients not in need of rapid remission should receive sequential chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    B    1a                                                                                                               [@R6464630-253] ,  [@R6464630-254]

  b\) A combination therapy consisting of chemotherapy and bevacizumab may improve progression-free survival as a first-line therapy, but this approach is associated with a higher rate of side effects and has no impact on overall survival.   0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1a   [@R6464630-255] ,  [@R6464630-256] ,  [@R6464630-257] ,  [@R6464630-258] ,  [@R6464630-259] ,  [@R6464630-260]   

  c\) Polychemotherapy or chemotherapy + bevacizumab may be administered to patients with severe symptoms and rapid tumor growth or aggressive tumor behavior, i.e. to patients who urgently require remission.                                   0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1a   [@R6464630-253] ,  [@R6464630-261]                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

##### 2.2.2.1  Bevacizumab for metastatic breast cancer (1st line)

In summary, higher rates of remission and an improved PFS (but no survival benefit) has been reported for additional therapy with bevacizumab, which seems to indicate that combination therapy is the appropriate treatment for patients in urgent need of remission and no combination of risk factors predisposing them to side effects (no previous history of uncontrolled arterial hypertension, cerebrovascular ischemia and deep vein thrombosis). See the long version for more details.

##### 2.2.2.2  Regimens

Specific information on the regimens are available in the long version of this guideline (in German).

  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                                                              EG
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.25.   Possible monotherapies can consist of the following substances: alkylating agents, anthraquinones, anthracyclines (also in liposomal form), eribulin, fluoropyrimidine, platinum complexes, taxanes, and vinorelbine. These substances can be combined with each another or with further substances for polychemotherapy. However, patients should only be treated with combinations that have previously been investigated in trials.   EC

#### 2.2.3  Metastatic HER2-positive breast cancer

  No.     Recommendations/ Statements                                                                                                                     EG   LoE   Sources
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- ------------------------------------
  5.26.   Systemic therapy after R0 resection of loco-regional recurrence must be considered to prolong the disease-free interval and overall survival.   B    1a    [@R6464630-262] ,  [@R6464630-263]
  5.27.   First-line therapy for metastasized HER2-positive breast cancer should consist of a dual blockade with trastuzumab/pertuzumab and a taxane.     B    1b    [@R6464630-262]
  5.28.   Second-line therapy for metastasized HER2-positive breast cancer should consist of therapy with T-DM1.                                          B    1b    [@R6464630-262]

#### 2.2.4  Specific locations of metastases

##### 2.2.4.1  Basic approach for distant metastasis

  No.     Recommendations/ Statements                                                                                                                                           EG
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.29.   The decision whether distant metastases should be treated with surgery or local ablation should be made on an individual basis by an interdisciplinary tumor board.   EC

##### 2.2.4.2  Special treatment for skeletal metastases

For the diagnosis and therapy of skeletal metastasis, please refer to the S3 guideline on Supportive Therapy for Oncology Patients ( <http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html> ).

**2.2.4.2.1  Indications for radiotherapy**

  No.     Recommendations/ Statements                                                                                                                                                                                                                                 EG
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.30.   Indications for local percutaneous radiotherapy for bone metastasis are:local pain,limited mobility,reduced stability (danger of fractures),s/p surgical stabilization,impending or existing neurological symptoms (e.g. compression of the spinal cord).   EC

**2.2.4.2.2  Indications for surgical therapy**

  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                     EG
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.31.   Indications for the surgical therapy of osseous manifestations may be:myeloid compression with neurological symptoms,pathological fracture,impending fracture (risk of fracture, e.g. based on Mirelsʼ scoring system, the Spinal Instability Neoplastic Scale \[SINS\]),solitary late metastasis,osteolysis which does not respond to radiotherapy,pain which does not respond to treatment.   EC

**2.2.4.2.3  Osteoprotective therapy**

  No.     Recommendations/ Statements                                                                                                          EG
  ------- ------------------------------------------------------------------------------------------------------------------------------------ ----
  5.32.   Osteoprotective therapy with bisphosphonates/denosumab should be carried out to prevent complications from osseous manifestations.   EC

##### 2.2.4.3  Treatment for brain metastasis

  No.     Recommendations/ Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    EG   LoE     Sources
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  5.26.   Single or solitary brain metastases should be resected if the patient has an otherwise favorable prognosis and the metastasis is in a location which permits its resection, and the risk of postoperative neurological deficits resulting from resection is low. Local fractionated radiotherapy or radiosurgery of the tumor bed should be subsequently carried out.Radiosurgery represents an alternative to resection for patients with single metastases if the metastases are not larger than 3 cm and there is no midline shift with symptoms of intracranial compression.Primary treatment of infratentorial metastasis consists of resection, which should be carried out to prevent imminent occlusive hydrocephalus.If the patient only has a limited number of brain metastases (between 2 -- 4) and their total volume can be treated with targeted radiation, initial radiosurgery is preferable to whole brain radiation therapy because of the lower negative impact on neurocognition, the shorter treatment time, and the better control rates. If surgery or radiosurgery cannot be carried out because of other negative prognostic criteria, the patient must receive whole brain radiation therapy alone. Whole brain radiation therapy alone must be used to treat patients with multiple brain metastases.A combination of resection or radiosurgery with whole brain radiation therapy improves the brain-specific progression-free survival compared to surgery or radiosurgery alone but does not improve overall survival. However, this approach can be considered in individual cases.It is not necessary to combine whole brain radiation therapy with radiosensitizing drugs.        1b/EC   [@R6464630-264] ,  [@R6464630-265] ,  [@R6464630-266] ,  [@R6464630-267] ,  [@R6464630-268] ,  [@R6464630-269] ,  [@R6464630-270] ,  [@R6464630-271] ,  [@R6464630-272] ,  [@R6464630-273]

  No.     Recommendations/ Statements                                                                                                                                                                   EG
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  5.34.   If cerebral metastasis is present, the patient should also receive systemic therapy (chemotherapy/endocrine therapy/anti-HER2 therapy) in addition to local therapy (surgery/radiotherapy).   EC

##### 2.2.4.4  Treatment for liver metastases

  No.     Recommendations/ Statements                                                                                                                                                                                                                 EG   LoE   Sources
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  5.35.   If the patient has liver metastases, resection or another form of local therapy (RFA, TACE, SBRT, SIRT) may be indicated in individual cases; the preconditions for this are:no disseminated metastasescontrolled extrahepatic metastasis   0    3b    [@R6464630-274] ,  [@R6464630-275] ,  [@R6464630-276] ,  [@R6464630-277] ,  [@R6464630-278] ,  [@R6464630-279] ,  [@R6464630-280] ,  [@R6464630-281] ,  [@R6464630-282] ,  [@R6464630-283] ,  [@R6464630-284] ,  [@R6464630-285]

##### 2.2.4.5  Treatment for lung metastases

  No.     Recommendations/ Statements                                                                                                                                                                                                             EG   LoE   Sources
  ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ----- ---------------------------------------------------------------------------------------------
  5.36.   Resection or another local therapy (RFA, stereotactic radiotherapy) may be indicated to treat individual patients with lung metastases; the preconditions for this are:no disseminated metastasescontrolled extrapulmonary metastasis   0    4     [@R6464630-286] ,  [@R6464630-287] ,  [@R6464630-288] ,  [@R6464630-289] ,  [@R6464630-290]

**2.2.4.5.1  Malignant pleural effusion**

  No.     Recommendations/ Statements                                                                       EG   LoE   Sources
  ------- ------------------------------------------------------------------------------------------------- ---- ----- -----------------
  5.37.   Patients with pleural carcinosis and symptomatic pleural effusions must be offered pleurodesis.   A    1a    [@R6464630-291]

##### 2.2.4.6  Skin and soft tissue metastasis

  No.     Recommendations/ Statements                                                                                                          EG
  ------- ------------------------------------------------------------------------------------------------------------------------------------ ----
  5.34.   Surgical excision or another form of local therapy (e.g. radiotherapy) can be considered to treat skin and soft tissue metastasis.   EC
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Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) -- Teil 2 mit Empfehlungen zur Therapie des primären, rezidivierten und fortgeschrittenen Mammakarzinoms

**Ziele** Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.

**Methode** Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-Fragen (PICO: Patients/Interventions/Control/Outcome), systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen -- und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.

**Empfehlungen** Teil 2 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Therapie des primären, rezidivierten und metastasierten Mammakarzinoms: Die lokoregionären Therapien erfahren in der aktuellen Leitlinie eine Deeskalation. Neben einer Verringerung des Sicherheitsabstandes bei den operativen Verfahren gibt die Leitlinie auch Empfehlungen zu einer reduzierten Radikalität bei axillären Interventionen. Die Systemtherapie richtet sich nach den tumorbiologischen Eigenschaften, neue Substanzen stehen insbesondere beim metastatierten Mammakarzinom zur Verfügung.
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Leitliniengruppe
================

Die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. ist mit der deutschen Krebsgesellschaft (DKG) federführende Fachgesellschaft dieser LL. Die hier vorgestellte Aktualisierung der Leitlinie wurde im Rahmen des Leitlinienprogramms Onkologie (OL-Programms) durch die Deutsche Krebshilfe gefördert. Die Mitglieder der Leitlinien-Steuergruppe ( [Tab. 1](#TB6464630DE-1){ref-type="table"} ), die von den teilnehmenden Fachgesellschaften und Organisationen ( [Tab. 2](#TB6464630DE-2){ref-type="table"} ) benannten sowie die von der Steuergruppe eingeladenen Experten ( [Tab. 3](#TB6464630DE-3){ref-type="table"} ) stellten die Mitglieder der Arbeitsgruppen und sind die Autoren der LL. Stimmberechtigt in den Abstimmungsprozessen (Konsensusverfahren) waren kapitelweise nur die von den teilnehmenden Fachgesellschaften und Organisationen benannten Mandatsträger nach Offenlegung und Ausschluss von Interessenkonflikten. Die Leitlinie wurde unter direkter Beteiligung von 4 Patientenvertreterinnen erstellt.

###### 

**Tab. 1**  Steuergruppe.

                                                                           Name                                              Stadt
  ------------------------------------------------------------------------ ------------------------------------------------- --------------------
  1                                                                        Prof. Dr. Ute-Susann Albert                       Marburg
  2                                                                        Prof. Dr. Wilfried Budach                         Düsseldorf
  3                                                                        Dr. Markus Follmann, MPH, M. Sc.                  Berlin
  4                                                                        Prof. Dr. Wolfgang Janni                          Ulm
  5                                                                        Prof. Dr. Ina Kopp                                Marburg
  6                                                                        Prof. Dr. Rolf Kreienberg                         Landshut
  7                                                                        PD Dr. Mathias Krockenberger                      Würzburg
  8                                                                        Prof. Dr. Thorsten Kühn                           Esslingen
  9                                                                        Dipl.-Soz. Wiss. Thomas Langer                    Berlin
  10                                                                       Dr. Monika Nothacker                              Marburg
  11                                                                       Prof. Dr. Anton Scharl                            Amberg
  12                                                                       Prof. Dr. Ingrid Schreer                          Hamburg-Eimsbüttel
  13                                                                       Prof. Dr. Achim Wöckel (Leitlinienkoordination)   Würzburg
  methodische Beratung: Prof. Dr. P. U. Heuschmann, Universität Würzburg                                                     

###### 

**Tab. 2**  Beteiligte Fachgesellschaften und Organisationen.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fachgesellschaften                                                                       1\. Mandatsträger                                              2\. Mandatsträger (Vertreter)
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------
  AG Radiologische Onkologie (ARO)                                                         **Prof. Dr. Wilfried Budach** , Düsseldorf                     **Prof. Dr. Frederik Wenz** , Mannheim

  AG Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin (ASORS)       **Prof. Dr. Hartmut Link** , Kaiserslautern                    **Prof. Dr. Oliver Rick** , Bad Wildungen

  Arbeitsgemeinschaft Deutscher Tumorzentren e. V. (ADT)                                   **Prof. Dr. Jutta Engel** , München                            **Prof. Dr. Dieter Hölzel** , München

  Arbeitsgemeinschaft für gynäkologische Onkologie (AGO)                                   **Prof. Dr. Tanja Fehm** , Düsseldorf                          **Prof. Dr. Anton Scharl** , Amberg

  AG Prävention und Integrative Onkologie (PRiO)                                           **Prof. Dr. Volker Hanf** , Fürth                              **Prof. Dr. Karsten Münstedt** , Offenburg

  Arbeitsgemeinschaft für Psychoonkologie in der Deutschen Krebsgesellschaft e. V. (PSO)   **Prof. Dr. Joachim Weis** , Freiburg                          

  Arbeitsgemeinschaft Internistische Onkologie (AIO)                                       **Dr. Anja Welt** , Essen                                      **Dr. Matthias Zaiss** , Freiburg

  Arbeitskreis Frauengesundheit (AKF)                                                      **Prof. Dr. Anke Steckelberg** , Halle                         **Gudrun Kemper** , Berlin

  Berufsverband Deutscher Strahlentherapeuten e. V. (BVDST)                                **Prof. Dr. Petra Feyer** , Berlin                             **Prof. Dr. Volker Budach** , Berlin

  Berufsverband für Frauenärzte e. V.                                                      **Dr. Klaus König** , Steinbach                                

  BRCA-Netzwerk e. V.                                                                      **Andrea Hahne** , Bonn                                        **Traudl Baumgartner** , Bonn

  Deutsche Gesellschaft für Pathologie                                                     **Prof. Dr. Hans H. Kreipe** , Hannover                        **Prof. Dr. Carsten Denkert** , Berlin

  Chirurgische AG für Onkologie (CAO-V)                                                    **Prof. Dr. Wolfram Trudo Knoefel** , Düsseldorf               

  Deutsche Gesellschaft für Geriatrie (DGG)                                                **Prof. Dr. Michael Denkinger** , Ulm                          

  Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)                            **Prof. Dr. Sara Brucker** , Tübingen                          **Prof. Dr. Bernd Gerber** , Rostock

  Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)                               **Prof. Dr. Diana Lüftner** , Berlin                           **Prof. Dr. Hans Tesch** , Frankfurt

  Deutsche Gesellschaft für Nuklearmedizin (DGN)                                           **Prof. Dr. Andreas Buck**                                     

  Deutsche Gesellschaft für Humangenetik e. V. (GfH)                                       **Prof. Dr. Christian Kubisch** , Hamburg                      

  Deutsche Gesellschaft für Palliativmedizin (DGP)                                         **Dr. Christina Gerlach** , M. Sc., Mainz                      **Dr. Susanne Hirsmüller** , M. Sc., Düsseldorf

  Bundesverband Deutscher Pathologen e. V.                                                 **Prof. Dr. Annette Lebeau** , Hamburg                         **Prof. Dr. Hans-Peter Sinn** , Heidelberg

  Deutsche Gesellschaft für psychosomatische Frauenheilkunde und Geburtshilfe (DGPFG)      **PD Dr. Friederike Siedentopf** , Berlin                      

  Deutsche Gesellschaft für Radioonkologie (DEGRO)                                         **Prof. Dr. Cordula Petersen** , Hamburg                       **Prof. Dr. Jürgen Dunst** , Kiel

  Deutsche Gesellschaft für Rehabilitationswissenschaften (DGRW)                           **Prof. Dr. Hans Helge Bartsch** , Freiburg                    

  Deutsche Gesellschaft für Senologie (DGS)                                                **Prof. Dr. Rüdiger Schulz-Wendtland** , Erlangen              

  Deutsche Gesellschaft für Ultraschall in der Medizin e. V. (DEGUM)                       **Prof. Dr. Markus Hahn** , Tübingen                           

  Deutsche Röntgengesellschaft e. V.                                                       **Prof. Dr. Markus Müller-Schimpfle** , Frankfurt              bis 31.12.16: **Prof. Dr. Ulrich Bick** , Berlin\
                                                                                                                                                          ab 01.01.17: **PD Dr. E. Fallenberg** , Berlin

  Deutscher Verband für Physiotherapie e. V. (ZVK)                                         **Ulla Henscher** , Hannover                                   **Reina Tholen** , Köln

  Frauenselbsthilfe nach Krebs                                                             **Dr. Renza Roncarati** , Bonn                                 **Roswita Hung** , Wolfsburg

  Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GEKID)            **Prof. Dr. Alexander Katalinic** , Lübeck                     

  Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgie (DGPRÄC)        **Prof. Dr. Christoph Heitmann** , München                     

  Gynécologie Suisse (SGGG)                                                                **Dr. Christoph Honegger** , Baar                              

  Konferenz Onkologischer Kranken- und Kinderkrankenpflege (KOK)                           **Kerstin Paradies** , Hamburg                                 

  Österreichische Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG)                    **Prof. Dr. Vesna Bjelic-Radisic** , Graz                      

  Ultraschalldiagnostik in Gynäkologie und Geburtshilfe (ARGUS)                            **Prof. Dr. med. Dr. h. c. Friedrich Degenhardt** , Hannover   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Tab. 3**  Experten in beratender Funktion und weitere Mitarbeiter.

  Name                                                                                                                    Stadt
  ----------------------------------------------------------------------------------------------------------------------- ---------------
  **Experten in beratender Funktion**                                                                                     
  PD Dr. Freerk Baumann                                                                                                   Köln
  Prof. Dr. Matthias W. Beckmann                                                                                          Erlangen
  Prof. Dr. Jens Blohmer                                                                                                  Berlin
  Prof. Dr. Peter Fasching                                                                                                Erlangen
  Prof. Dr. Nadia Harbeck                                                                                                 München
  Prof. Dr. Peyman Hadji                                                                                                  Frankfurt
  Prof. Dr. Hans Hauner                                                                                                   München
  Prof. Dr. Sylvia Heywang-Köbrunner                                                                                      München
  Prof. Dr. Jens Huober                                                                                                   Ulm
  Prof. Dr. Jutta Hübner                                                                                                  Jena
  Prof. Dr. Christian Jackisch                                                                                            Offenbach
  Prof. Dr. Sibylle Loibl                                                                                                 Neu-Isenburg
  Prof. Dr. Hans-Jürgen Lück                                                                                              Hannover
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ADH

:   (intra-)duktale atypische Hyperplasie

AI

:   Aromatase Inhibitor

AML

:   akute myeloische Leukämie

APBI

:   Accelerated partial Breast Irradiation

ASCO

:   American Society of Clinical Oncology

ATL

:   Aktivitäten des täglichen Lebens

AUC

:   Area under the Curve

BÄK

:   Bundesärztekammer

bds

:   beiderseits

BET

:   brusterhaltende Therapie

BI-RADS

:   Breast Imaging Reporting and Data System

BMI

:   Body-Mass-Index

BPM

:   beidseitige prophylaktische Mastektomie

BPSO

:   beidseitige prophylaktische Salpingo-Oophorektomie

BRCA1/2

:   Breast Cancer associated Gene 1/2

BWS

:   Brustwirbelsäule

CAM

:   komplementäre und alternative Methoden

CAP

:   College of American Pathologists

CGA

:   Comprehensive geriatric Assessment

CHF

:   chronische Herzinsuffizienz

CIPN

:   chemotherapieinduzierte periphere Neuropathie

CISH

:   Chromogene-in-situ-Hybridisierung

CNB

:   Core Needle Biopsy

CT

:   Computertomografie

DCIS

:   duktales Carcinoma in situ

DBT

:   digitale Brusttomosynthese

DFS

:   Disease free Survival

DGS

:   Deutsche Gesellschaft für Senologie

DKG

:   Deutsche Krebsgesellschaft

ECE

:   extrakapsuläres Tumorwachstum

EIC

:   extensive intraduktale Komponente

EK

:   Expertenkonsens

ER

:   Estrogenrezeptor

ESA

:   erythropoesestimulierende Agenzien

ESAS

:   Edmonton Symptom Assessments Scale

ET

:   Östrogentherapie

FEA

:   flache Epithelatypie

FISH

:   Fluoreszenz-in-situ-Hybridisierung

FN

:   febrile Neutropenie

FNA

:   Feinnadelaspiration

FNB

:   Feinnadelbiopsie

G-CSF

:   Granulozytenkoloniestimulierender Faktor

GnRHa

:   Gonadotropin-releasing Hormone Agonist

HADS

:   Hospital Anxiety and Depression Scale

HER2

:   Human epidermal Growth Factor Receptor 2

HT

:   Hormontherapie

IARC

:   International Agency for Research on Cancer

IBC

:   inflammatorisches Mammakarzinom

iFE

:   intensivierte Früherkennung

IHC

:   Immunhistochemie

IMRT

:   intensitätsmodulierte Radiotherapie

IORT

:   intraoperative Strahlentherapie

IQWIG

:   Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

ISH

:   In-situ-Hybridisierung

ITC

:   intrathekale Chemotherapie

KD

:   kognitive Dysfunktion

KM-MRT

:   Kontrastmittel-Magnetresonanztomografie

KPE

:   Komplexe Physikalische Entstauungstherapie

LABC

:   Locally advanced Breast Cancer

LCIS

:   lobuläres Carcinoma in situ

LK

:   Lymphknoten

LL

:   Leitlinie

LN

:   lobuläre Neoplasie

LoE

:   Level of Evidence

LVEF

:   linksventrikuläre Ejektionsfraktion

LVI

:   (Lymph-)Gefäßinvasion

LWS

:   Lendenwirbelsäule

MAK

:   Mamillen-Areola-Komplex

MDS

:   myelodysplastisches Syndrom

MG

:   Mammografie

MRT

:   Magnetresonanztomografie

MSP

:   Mammografie-Screening-Programm

NACT

:   neoadjuvante Chemotherapie

NCCN

:   National Comprehensive Cancer Network

NICE

:   National Institute for Health and Clinical Excellence

NNT

:   Number needed to treat

NZGG

:   New Zealand Guidelines Group

OP

:   Operation

OS

:   Overall Survival

PBI

:   Partial Breast Irradiation

pCR

:   pathologische Komplettremission

PET

:   Positronenemissionstomografie

PFS

:   progressionsfreies Überleben

PI

:   Proliferationsindex

PMRT

:   postoperative Strahlentherapie

PNP

:   Polyneuropathie

POS

:   Palliative Outcome Scale

PR

:   Progesteronrezeptor

PST

:   primär systemische Therapie

QoL

:   Quality of Life

RCT

:   randomisierte kontrollierte Studie

RFA

:   Radiofrequenzablation

ROR

:   Risk of Recurrence

RR

:   relatives Risiko

RS

:   Recurrence Score

SABCS

:   San Antonio Breast Cancer Symposium

SBRT

:   stereotaktische Bestrahlung

SGB

:   Sozialgesetzbuch

SIB

:   simultan integrierter Boost

SIGN

:   Scottish Intercollegiate Guidelines Network

SISH

:   silberverstärkte In-situ-Hybridisierung

SLN

:   Sentinel-Lymphknoten

SLNB

:   Sentinel Lymph Node Biopsy

SSM

:   Skin-sparing Mastectomy

TACE

:   transarterielle Chemoembolisation

TILs

:   tumorinfiltrierende Lymphozyten

TNBC

:   triple-negative Breast Cancer

TNM-Klassifikation

:   Tumour-Node-Metastasis-Klassifikation

UICC

:   Union for International Cancer Control

US

:   Ultraschall

VMAT

:   Volu-Metric-Arc-Therapie

WHO

:   Weltgesundheitsorganisation

ZNS

:   Zentralnervensystem  

II  Leitlinienverwendung
========================

Fragen und Ziele
================

Die wesentliche Rationale für die Aktualisierung der interdisziplinären Leitlinie (LL) ist die gleichbleibend hohe epidemiologische Bedeutung des Mammakarzinoms und die damit verbundene Krankheitslast. In diesem Zusammenhang sind die Auswirkungen neuer Versorgungskonzepte in ihrer Umsetzung zu prüfen.

Versorgungsbereich
==================

Die LL betrifft die ambulante, stationäre und rehabilitative Versorgung.

Patienten/innenzielgruppe
=========================

Die Empfehlungen der LL richten sich an alle an Brustkrebs erkrankten Frauen und Männern sowie deren Angehörige.

Anwenderzielgruppe/Adressaten
=============================

Die Empfehlungen der LL richten sich an alle Ärzte und Angehörige von Berufsgruppen, die mit der Versorgung von Bürgerinnen im Rahmen der Früherkennung und Patientinnen und Patienten mit Brustkrebs befasst sind (Gynäkologen, Allgemeinmediziner, Humangenetikern, Radiologen, Pathologen, Radioonkologen, Hämatoonkologen, Psychoonkologen, Physiotherapeuten, Pflegekräfte etc.).

Verabschiedung und Gültigkeitsdauer
===================================

Diese Leitlinie besitzt eine Gültigkeitsdauer vom 01.12.2017 bis 30.11.2022. Diese Dauer ist aufgrund der inhaltlichen Zusammenhänge geschätzt. Der Bedarf zur Aktualisierung der Leitlinie ergibt sich zudem aus der Existenz neuer wissenschaftlicher Erkenntnisse und der Weiterentwicklung in der LL-Methodik. Zudem ist in regelmäßigen Abständen eine redaktionelle und inhaltliche Prüfung und Überarbeitung der Kernaussagen und Empfehlungen der LL erforderlich.

III  Leitlinienmethodik
=======================

Grundlagen
==========

Die Methodik zur Erstellung dieser Leitlinie wird durch die Vergabe der Stufenklassifikation vorgegeben. Das AWMF-Regelwerk (Version 1.0) gibt entsprechende Regelungen vor. Es wird zwischen der niedrigsten Stufe (S1), der mittleren Stufe (S2) und der höchsten Stufe (S3) unterschieden. Die niedrigste Klasse definiert sich durch eine Zusammenstellung von Handlungsempfehlungen, erstellt durch eine nicht repräsentative Expertengruppe. Im Jahr 2004 wurde die Stufe S2 in die systematische evidenzrecherchebasierte (S2e) oder strukturelle konsensbasierte Unterstufe (S2k) gegliedert. In der höchsten Stufe S3 vereinigen sich beide Verfahren. Diese Leitlinie entspricht der Stufe S3.

Evidenzgraduierung
==================

Zur Klassifikation des Verzerrungsrisikos der identifizierten Studien wurde in dieser Leitlinie das System des Oxford Centre for Evidence-based Medicine in der Version von 2009 verwendet (Level 1 -- 5). Dieses System sieht die Klassifikation der Studien für verschiedene klinische Fragestellungen (Nutzen von Therapie, prognostische Aussagekraft, diagnostische Wertigkeit) vor: detaillierte Inhalte, Abkürzungen und Notes siehe: <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>

Empfehlungsgraduierung
======================

Während mit der Darlegung der Qualität der Evidenz (Evidenzstärke) die Belastbarkeit der publizierten Daten und damit das Ausmaß an Sicherheit/Unsicherheit des Wissens ausgedrückt wird, ist die Darlegung der Empfehlungsgrade Ausdruck des Ergebnisses der Abwägung erwünschter und unerwünschter Konsequenzen alternativer Vorgehensweisen. In der Leitlinie werden zu allen evidenzbasierten Statements und Empfehlungen das Evidenzlevel der zugrunde liegenden Studien sowie bei Empfehlungen zusätzlich die Stärke der Empfehlung (Empfehlungsgrad) ausgewiesen. Hinsichtlich der Stärke der Empfehlung werden in dieser Leitlinie 3 Empfehlungsgrade unterschieden ( [Tab. 4](#TB6464630DE-4){ref-type="table"} ), die sich auch in der Formulierung der Empfehlungen jeweils widerspiegeln.

###### 

**Tab. 4**  Schema der Empfehlungsgraduierung.

  Empfehlungsgrad   Empfehlungsgraduierung                           
  ----------------- ------------------------------------------------ ----------------------
  A                 starke Empfehlung mit hoher Verbindlichkeit      soll/ soll nicht
  B                 Empfehlung mit mittlerer Verbindlichkeit         sollte/ sollte nicht
  0                 offene Empfehlung mit geringer Verbindlichkeit   kann/ kann nicht

Statements
==========

Als Statements werden Darlegungen oder Erläuterungen von spezifischen Sachverhalten oder Fragestellungen ohne unmittelbare Handlungsaufforderung bezeichnet. Sie werden entsprechend der Vorgehensweise bei den Empfehlungen im Rahmen eines formalen Konsensusverfahrens verabschiedet und können entweder auf Studienergebnissen oder auf Expertenmeinungen beruhen.

Expertenkonsens
===============

Wie der Name bereits ausdrückt, sind hier Konsensusentscheidungen speziell für Empfehlungen/Statements ohne vorige systemische Literaturrecherche (S2k) oder aufgrund von fehlender Evidenz (S2e/S3) gemeint. Der zu benutzende Expertenkonsens (EK) ist gleichbedeutend mit den Begrifflichkeiten aus anderen Leitlinien wie „Good Clinical Practice" (GCP) oder „klinischer Konsensuspunkt"(KKP). Die Empfehlungsstärke graduiert sich gleichermaßen wie bereits im Kapitel Empfehlungsgraduierung beschrieben ohne die Benutzung der aufgezeigten Symbolik, sondern rein semantisch („soll"/„soll nicht" bzw. „sollte"/„sollte nicht" oder „kann"/„kann nicht").

Leitlinienreport
================

Zur Bearbeitung der Themenkomplexe wurde für etwa 80% der Statements und Empfehlungen eine Leitlinienadaptation gemäß dem AWMF-Regelwerk vorgesehen. Hierfür wurde systematisch nach Quell-LL recherchiert, die spezifisch für Patientinnen mit Brustkrebs entwickelt wurden und nach November 2013 veröffentlicht wurden. Hier erfolgte ein Abgleich mit dem IQWIG-Leitlinienbericht Nr. 224 (Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für das DMP Brustkrebs). Ein weiteres Einschlusskriterium war die Erfüllung methodischer Standards. LL wurden eingeschlossen, wenn sie mindestens 50% der Domäne 3 (Rigour of Development) des AGREE-II-Instruments erfüllten. Für Empfehlungen, die nicht adaptiert werden konnten bzw. neu generiert werden mussten, wurden eine entsprechende Recherche und Evidenzbewertungen nach dem AWMF-Regelwerk (systematische Recherche, Selektion, Erstellung von Evidenztabellen) festgelegt. Für diese neu zu entwerfenden Empfehlungen und Statements erfolgten die Formulierung der entsprechenden Schlüsselfragen und die systematische Recherche zunächst auf Basis von aggregierten Evidenzquellen (Metaanalysen, systematische Reviews, etc.), ggf. auch auf Einzelpublikationsbasis. Entsprechende Titel- und Abstractlisten wurden bis zur Identifikation der Volltexte von 2 unabhängigen Ratern selektiert. Nach Ablauf der Recherche- und Selektionsprozesse wurden von der Methodengruppe (hierfür wurde durch die Förderung eigens eine Wissenschaftlerin eingestellt) entsprechende Evidenztabellen als Grundlage der Konsensuskonferenzen angefertigt. Als Schema der Evidenzgraduierung wurde die Klassifikation des Oxford Centre for Evidence-based Medicine (Version 2009) verwendet. Die Verabschiedung von Empfehlungen und Statements sowie die Festlegung der Empfehlungsgrade ( [Tab. 4](#TB6464630DE-4){ref-type="table"} ) erfolgten bei der Aktualisierung der LL im Rahmen von 2 strukturierten Konsensuskonferenzen mit vorgeschalteter Online-Vorabstimmung.

Entsprechende Recherchestrategien und Selektionsprozesse der Literatur bis hin zur Formulierung und Graduierung der Empfehlungen finden sich im Leitlinienreport.

IV  Leitlinie
=============

1  Therapie des primären Mammakarzinoms
=======================================

1.1  Operative Therapie des invasiven Karzinoms
===============================================

1.2  Adjuvante Strahlentherapie des Mammakarzinoms
==================================================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                                                                EG    LoE   Quellen
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----- ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  4.36.   Nach brusterhaltender Operation wegen eines invasiven Karzinoms soll eine Bestrahlung der betroffenen Brust durchgeführt werden.\                                                                                                                                                                                                                                                                      A     1a    [@R6464630-40] ,  [@R6464630-41] ,  [@R6464630-42] ,  [@R6464630-43] ,  [@R6464630-44] ,  [@R6464630-45] ,  [@R6464630-46] ,  [@R6464630-47]
          Bei Patientinnen mit eindeutig begrenzter Lebenserwartung (\< 10 Jahre) und einem kleinen (pT1), nodalnegativen (pN0), hormonrezeptorpositiven HER2-negativen Tumor mit endokriner adjuvanter Therapie, freie Schnittränder vorausgesetzt, kann unter Inkaufnahme eines erhöhten Lokalrezidivrisikos nach individueller Beratung auf die Strahlentherapie verzichtet werden.\                                      
          Hinweis für alle Empfehlungen: Alle Einzelpositionen sind „oder"-Verknüpfungen. „Und"-Verknüpfungen sind mit einem „und" dargestellt.                                                                                                                                                                                                                                                                              

  4.37.   Die Radiotherapie der Brust sollte in Hypofraktionierung (Gesamtdosis ca. 40 Gy in ca. 15 -- 16 Fraktionen in ca. 3 bis 5 Wochen) oder kann in konventioneller Fraktionierung (Gesamtdosis ca. 50 Gy in ca. 25 -- 28 Fraktionen in ca. 5 -- 6 Wochen) erfolgen.                                                                                                                                        B/0   1a    [@R6464630-48] ,  [@R6464630-49] ,  [@R6464630-50] ,  [@R6464630-51] ,  [@R6464630-52] ,  [@R6464630-53] ,  [@R6464630-54]

  4.38.   Eine lokale Dosisaufsättigung (Boost-Bestrahlung) des Tumorbettes senkt die lokale Rezidivrate in der Brust, ohne dadurch einen signifikanten Überlebensvorteil zu bewirken.\                                                                                                                                                                                                                          A/B   1a    [@R6464630-55] ,  [@R6464630-56] ,  [@R6464630-57] ,  [@R6464630-58]
          Die Boostbestrahlungsoll daher bei allen ≤ 50 Jahre alten Patientinnen undsollte bei \> 51 Jahre alten Patientinnen nur bei erhöhtem lokalen Rückfallrisiko erfolgen (G3, HER2-positiv, triple-negativ, \>T1).                                                                                                                                                                                                     

  4.39.   Eine alleinige Teilbrustbestrahlung (als Alternative zur Nachbestrahlung der ganzen Brust) kann bei Patientinnen mit niedrigem Rezidivrisiko durchgeführt werden.                                                                                                                                                                                                                                      0     1a    [@R6464630-59] ,  [@R6464630-60] ,  [@R6464630-61] ,  [@R6464630-62] ,  [@R6464630-63] ,  [@R6464630-64]

  4.40.   Die postoperative Radiotherapie der Brustwand nach Mastektomie senkt das Risiko eines lokoregionären Rezidivs und verbessert das Gesamtüberleben bei lokal fortgeschrittenen und nodal positiven Mammakarzinomen.                                                                                                                                                                                      A     1a    [@R6464630-65]

  4.41.   Bei folgenden Situationen soll die Strahlentherapie der Brustwand nach Mastektomie indiziert werden:\                                                                                                                                                                                                                                                                                                  A     1a    [@R6464630-65] ,  [@R6464630-66] ,  [@R6464630-67] ,  [@R6464630-68] ,  [@R6464630-69] ,  [@R6464630-70] ,  [@R6464630-71] ,  [@R6464630-72] ,  [@R6464630-73] ,  [@R6464630-74] ,  [@R6464630-75] ,  [@R6464630-76] ,  [@R6464630-77] ,  [@R6464630-78] ,  [@R6464630-79]
          pT4pT3 pN0 R0 bei Vorliegen von Risikofaktoren (Lymphgefäßinvasion \[L1\], Grading G3, prämenopausal, Alter \< 50 Jahre)R1-/R2-Resektion und fehlender Möglichkeit der sanierenden Nachresektiona) Bei mehr als 3 befallenen axillären Lymphknoten soll eine Postmastektomiebestrahlung regelhaft durchgeführt werden.\                                                                                            
          b) Bei 1 -- 3 tumorbefallenen axillären Lymphknoten soll eine Postmastektomiebestrahlung durchgeführt werden, wenn ein erhöhtes Rezidivrisiko vorliegt (z. B. wenn HER2-positiv, triple-negativ, G3, L1, Ki-67 \> 30%, \> 25% der entfernten Lymphknoten tumorbefallen; Alter ≤ 45 Jahren mit zusätzlichen Risikofaktoren wie medialer Tumorlokalisation oder Tumorgröße \> 2 cm, oder ER-negativ).\               
          c) Bei 1 -- 3 tumorbefallenen axillären Lymphknoten und Tumoren mit geringem Lokalrezidivrisiko (pT1, G1, ER-positiv, HER2-negativ, wenigstens 3 Eigenschaften müssen zutreffen) sollte auf die PMRT verzichtet werden.\                                                                                                                                                                                           
          d) Bei allen anderen Patientinnen mit 1 -- 3 tumorbefallenen axillären Lymphknoten soll die individuelle Indikation interdisziplinär festgelegt werden.                                                                                                                                                                                                                                                            

  4.42.   Nach primärer (neoadjuvanter) systemischer Therapie soll sich die Indikation zur Postmastektomie-Radiotherapie am prätherapeutischen klinischen Stadium orientieren; bei pCR (ypT0 und ypN0) soll die Indikation im interdisziplinären Tumorboard abhängig vom Risikoprofil festgelegt werden.                                                                                                         A     1a    [@R6464630-80] ,  [@R6464630-81] ,  [@R6464630-82] ,  [@R6464630-83]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  prätherapeutisch              posttherapeutisch            RT-BET ^1^   PMRT ^2^          RT-LAW ^3^
  ----------------------------- ---------------------------- ------------ ----------------- ------------
  lokal fortgeschritten         pCR/no pCR                   ja           ja                ja
  cT1/2 cN1+                    ypT1+ o. ypN1+ (no pCR)      ja           ja                ja
  cT1/2 cN1+                    ypT0/is ypN0 (SLNE ≥ 3 LK)   ja           Risikofälle ^4^   
  cT1/2 cN0 (Sonogr. obligat)   ypT0/is ypN0 (SLNE ≥ 3 LK)   ja           nein              nein

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.                                                                                                                                                                                                                                                                            Empfehlungen/Statements                                                                                                                                                                                                                                                                                                                                           EG    LoE                                                                                                                          Quellen
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----- ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  4.43.                                                                                                                                                                                                                                                                          Die adjuvante Bestrahlung der regionalen Lymphabflussgebiete verbessert das krankheitsfreie Überleben und das Gesamtüberleben in Untergruppen von Patientinnen.                                                                                                                                                                                                         1a                                                                                                                           [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]

  4.44.                                                                                                                                                                                                                                                                          a\) Die Bestrahlung der supra-/infraklavikulären Lymphknoten kann bei Patientinnen mit pN0 oder pN1mi in folgender Situation erfolgen, sofern die folgenden Bedingungen alle erfüllt sind: prämenopausal und zentraler oder medialer Sitz und G2--3 und ER/PgR-negativ.                                                                                           0     2a/2b                                                                                                                        [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]

  b\) Die Bestrahlung der supra/infraklavikulären Lymphknoten sollte bei Patientinnen mit 1 -- 3 befallenen Lymphknoten in folgenden Situationen erfolgen:\                                                                                                                      B                                                                                                                                                                                                                                                                                                                                                                 2a    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   
  zentraler oder medialer Sitz und (G2--3 oder ER/PgR-negativ)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  prämenopausal, lateraler Sitz und (G2--3 oder ER/PgR-negativ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  c\) Die Bestrahlung der supra/infraklavikulären Lymphknoten soll generell bei Patientinnen mit \> 3 befallenen axillären Lymphknoten erfolgen.                                                                                                                                 A                                                                                                                                                                                                                                                                                                                                                                 2a    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   

  4.45.                                                                                                                                                                                                                                                                          a\) Die Bestrahlung der A.-mammaria-interna-Lymphknoten kann bei axillär pN0- oder axillär pN1mi-Patientinnen in folgender Situation erfolgen:prämenopausal und zentraler oder medialer Sitz und G2--3 und ER/PgR-negativ                                                                                                                                         0     2b                                                                                                                           [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]

  b\) Die Bestrahlung der A.-mammaria-interna-Lymphknoten sollte bei Patientinnen mit 1 -- 3 befallenen Lymphknoten in folgenden Situationen erfolgen:zentraler oder medialer Sitz und (G2--3 oder ER/PgR-negativ)prämenopausal, lateraler Sitz und (G2--3 oder ER/PgR-negativ   B                                                                                                                                                                                                                                                                                                                                                                 2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]                                       

  c\) Die Bestrahlung der A.-mammaria-interna-Lymphknoten sollte bei Patientinnen mit \> 3 befallenen axillären Lymphknoten in folgender Situation erfolgen:G2--3 oder ER/PgR-negativ                                                                                            B                                                                                                                                                                                                                                                                                                                                                                 2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88]                                       

  d\) Bei nachgewiesenem Befall der A.-mammaria-interna-Lymphknoten sollten diese bestrahlt werden.                                                                                                                                                                              B                                                                                                                                                                                                                                                                                                                                                                 2b    [@R6464630-84] ,  [@R6464630-85] ,  [@R6464630-86] ,  [@R6464630-87] ,  [@R6464630-88] ,  [@R6464630-89] ,  [@R6464630-90]   

  e\) Die Bestrahlung der A.-mammaria-interna-Lymphknoten soll bei erhöhtem kardialen Risiko oder einer Therapie mit Trastuzumab individuell interdisziplinär entschieden werden.                                                                                                A                                                                                                                                                                                                                                                                                                                                                                 4     [@R6464630-91] ,  [@R6464630-92]                                                                                             

  4.46.                                                                                                                                                                                                                                                                          Eine erweiterte axilläre Bestrahlung kann bei Patientinnen mit 1 -- 2 befallenen axillären Wächterlymphknoten erfolgen, sofern keine axilläre Dissektion durchgeführt oder interdisziplinär keine weitere lokale axilläre Therapie vereinbart wurde (analog ACOSOG Z0011). Die Entscheidung über das geeignete Vorgehen soll interdisziplinär getroffen werden.   0/A   2b                                                                                                                           [@R6464630-35] ,  [@R6464630-93] ,  [@R6464630-94] ,  [@R6464630-95]

  4.47.                                                                                                                                                                                                                                                                          Die Radiotherapie des Lymphabflusses sollte in konventioneller Fraktionierung (5 × wöchentlich 1,8 -- 2,0 Gy, Gesamtdosis ca. 50 Gy in ca. 5 -- 6 Wochen) oder kann in Hypofraktionierung (Gesamtdosis ca. 40 Gy in ca. 15 -- 16 Fraktionen in ca. 3 -- 5 Wochen) erfolgen.                                                                                       EK                                                                                                                                 

  4.48.                                                                                                                                                                                                                                                                          Bei Patientinnen mit primär inoperablen bzw. inflammatorischen Karzinomen soll eine primäre Systemtherapie, gefolgt von Operation und postoperativer Strahlentherapie oder bei weiter bestehender Inoperabilität alleiniger oder präoperativer Strahlentherapie durchgeführt werden.                                                                              A     1b                                                                                                                           [@R6464630-96] ,  [@R6464630-97]

  4.49.                                                                                                                                                                                                                                                                          a\) Postoperative Chemotherapie und Radiotherapie sollen sequenziell erfolgen.\                                                                                                                                                                                                                                                                                   A     1b                                                                                                                           [@R6464630-98] ,  [@R6464630-99] ,  [@R6464630-100] ,  [@R6464630-101]
                                                                                                                                                                                                                                                                                 Hinweis: Die Überlegenheit einer speziellen Sequenz (erst Chemotherapie bzw. erst Radiotherapie) ist nicht belegt. Für die klinische Praxis hat sich die Sequenz von Chemotherapie mit nachfolgender Radiotherapie etabliert.                                                                                                                                                                                                                                                                        

  b\) Bei alleiniger RT sollte diese innerhalb einer 8-wöchigen Frist postoperativ eingeleitet werden.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   [@R6464630-102] ,  [@R6464630-103]                                                                                           

  c\) Eine adjuvante endokrine Therapie kann unabhängig von der Radiotherapie eingeleitet werden. (1a)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  [@R6464630-91] ,  [@R6464630-92] ,  [@R6464630-104] ,  [@R6464630-105]                                                       
  Eine Therapie mit Trastuzumab kann während einer Strahlentherapie fortgeführt werden. Bei einer simultanen A.-mammaria-Lymphknoten-Bestrahlung soll das Vorgehen interdisziplinär festgelegt werden. (4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1.3  Systemische adjuvante Therapie (endokrine, Chemo-, Antikörpertherapie)
===========================================================================

1.4  Mammakarzinom in Schwangerschaft und Stillzeit, Schwangerschaft nach Mammakarzinom, Fertilitätserhalt
==========================================================================================================

1.5  Mammakarzinom der älteren Patientin
========================================

1.6  Mammakarzinom des Mannes
=============================

Die Diagnostik und Therapie des Mammakarzinoms des Mannes sollte interdisziplinär erfolgen und erfordert aufgrund der tumorbiologischen Eigenschaften und Ähnlichkeit zu dem Mammakarzinom der Frau gynäkoonkologische Fachexpertise. Eine interdisziplinäre Zusammenarbeit von Brustzentren, niedergelassenen Gynäkologen, Urologen und Andrologen wird insbesondere angeraten bei der Behandlung der sexuellen Störungen durch die Tamoxifentherapie, bei Männern mit BRCA-Mutationen [@R6464630-233] mit einem damit einhergehenden erhöhten Risiko für Prostatakrebs und bei Männern mit Brustkrebs, bei denen eine Behandlung des benignen Prostatasyndroms erfolgen soll [@R6464630-234] .

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nr.     Empfehlungen/Statements                                                                                                                                                                                                                                                                               EG
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----
  9.1.    a\) Eine frühzeitige ärztliche Konsultation soll durch Information von Männern über die Erkrankung, insbesondere über Symptome und Veränderungen der Brust und durch die Aufforderung zur Selbstbeobachtung gefördert werden.\                                                                        EK
          b) Die Basisdiagnostik soll bei Verdacht auf maligne Befunde durch Anamnese, klinische Untersuchung, Mammografie sowie Ultraschalldiagnostik der Brust und der Lymphabflussregionen erfolgen. Zum diagnostischen Einsatz der KM-MRT liegen keine Daten vor.\                                          
          c) Die weiterführende Diagnostik und das Staging/Ausbreitungsdiagnostik soll bei Brust- und Axillabefunden entsprechend der Empfehlung für Frauen erfolgen, wobei zum diagnostischen Einsatz von KM-MRT keine Daten vorliegen.                                                                        

  9.2.    a\) Die Operation hat die vollständige Tumorentfernung zum Ziel und sollte als Mastektomie durchgeführt werden. Bei günstigem Größenverhältnis zwischen Tumor und Brust sollte die Brusterhaltung erwogen werden.\                                                                                    EK
          b) Bei klinisch unauffälliger Axilla (cN0) soll eine Sentinel-Lymphknoten-Entfernung nach den gleichen Regeln wie bei der Frau vorgenommen werden.                                                                                                                                                    

  9.3.    Bei größeren Tumoren (≥ 2 cm), bei axillärem Lymphkotenbefall und bei negativem Hormonrezeptor soll eine adjuvante Radiotherapie der Brustwand und ggf. der Lymphabflusswege (Indikation wie bei der Frau) unabhängig vom Operationsverfahren erfolgen.                                               EK

  9.4.    Die adjuvante Chemotherapie sowie die Antikörpertherapie (anti-HER2) soll nach den gleichen Regeln wie bei der Frau indiziert und durchgeführt werden.                                                                                                                                                EK

  9.5.    Patienten mit einem hormonrezeptorpositiven Mammakarzinom sollen eine adjuvante endokrine Therapie mit Tamoxifen in der Regel über 5 Jahre erhalten. Für eine Behandlung über 5 Jahre hinaus liegen keine Daten vor. Analog zum weiblichen Mammakarzinom kann diese in Einzelfällen erwogen werden.   EK

  9.6.    a\) Die Therapie bei metastasierter Erkrankung sollte nach den gleichen Regeln wie bei der Frau erfolgen.\                                                                                                                                                                                            EK
          b) Es ist unklar, ob Aromatasehemmer ohne Suppression der testikulären Funktion beim Mann ausreichend wirksam sind. Daher sollten Aromatasehemmer in Kombination mit einer Suppression der testikulären Funktion gegeben werden.                                                                      

  9.7.    Die Teilnahme an Studien/Registern sollte Männern mit Brustkrebs angeboten und ermöglicht werden.                                                                                                                                                                                                     EK

  9.8.    Eine genetische Beratung soll allen Männern mit Brustkrebs empfohlen werden.                                                                                                                                                                                                                          EK

  9.9.    Die Ausgestaltung der Nachsorge einschließlich der bildgebenden Diagnostik soll in Analogie zum Vorgehen der Frauen erfolgen.                                                                                                                                                                         EK

  9.10.   Qualifizierte und sachdienliche genderspezifische Informationen (Print und Internet) sollten dem Patienten von dem behandelnden Fachpersonal zur Verfügung gestellt werden und der Zugang zum speziellen Angebot der Selbsthilfegruppen ermöglicht werden.                                            EK
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Tab. 5**  Risikofaktoren für Männer, an einem Mammakarzinom zu erkranken.

  ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alter                                                                                                  unimodale Altersverteilung mit der höchsten Inzidenz im 71. Lebensjahr
  Herkunft                                                                                               erhöhtes Risiko bei Afrikanern und karibischen Männern meist auch in fortgeschrittenen Stadien bei Erstdiagnose
  Keimbahnmutationen                                                                                     bei positiver Familienanamnese beider Geschlechter 2,5-faches Erkrankungsrisiko; BRCA2-Mutationen bei 4 -- 40% aller Fälle nachzuweisen; RAD51B-Gen-Alterationen erhöhen das Risiko um 50%
  endokrine Ursachen                                                                                     exogene Östrogenbelastung z. B. durch Hormontherapie für Transsexuelle, Behandlung des Prostatakarzinoms, berufliche Exposition
  erhöhte endogene Östrogensynthese: Klinefelter-Syndrom, Adipositas                                     
  erniedrigte Androgenspiegel: Orchidektomie, Hodenhochstand, mumpsassoziierte Orchitis, Leberzirrhose   
  Umwelt                                                                                                 Lifestyle: Adipositas, mangelnde Bewegung, exzessiver Alkoholkonsum
  Strahlenexposition: Nuklearwaffen, Radiotherapie, diagnostische Radiologie                             
  berufliche Exposition: hohe Temperaturen, Erdöl, Abgase                                                
  ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2  Therapie (Rezidiv/metastasiert)
==================================

2.1  Therapie des lokalen/lokoregionalen Rezidivs
=================================================

2.2  Fernmetastasen
===================

###### Herausgeber
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